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The aim of this research was to determine the potential of the Russian genome 
sequencing market on the basis of the new generation sequencer methodology. The 
author of this research took into account the theoretical data on the international 
development of the market for medical purposes and conducted a review of existing 
trends of development on the Russian market. Macro environment analysis was made 
on the base of PEST model.  
As part of the research, the system of trading of Russian state institutions in recent 
years has been carried out. Also expert assessments about market development, 
opinions of ordinary people and their preferences have been found out through 
interviews and e-polls. In addition, the analysis of the company's existing distribution 
network was made by interviews with their representatives to predict the possibility of 
promoting a new product through an established distribution network.  
The results of this research were the attempts to predict the demand for genome tests 
and market size of equipment for genome research under the influence of various 
factors and recommendations for Case Company for starting development and 
launching commercial activities in the genome sequencing market in Russia, in 
particular for medical diagnostic purposes. 
 
 
Keywords: genome test, genome sequencing Russian market, new generation 
sequencing, sequencer demand market, genome test demand, sequencer, PEST 
model. 
  
 
 
3 
 
Table of content  
 
1 INTRODUCTION ..................................................................................................................... 5 
1.1 Case company .............................................................................................................. 6 
1.2 The general essence of the method of genome research ............................................. 8 
1.3 Objectives of the study ................................................................................................. 8 
1.4 Definition of products for research ................................................................................ 9 
1.5 Phenomenon of the thesis topic .................................................................................. 10 
1.6 Delimitations of the study ............................................................................................ 11 
1.7 Structure of the thesis ................................................................................................. 11 
2 MACRO ENVIRONMENT ANALYSES .............................................................................. 12 
2.1 Technological factors of influence on the market ........................................................ 13 
2.1.1 Basic history of genome sequencing ................................................................... 13 
2.1.2 The technological development of genome research on international market ...... 14 
2.1.3 Features of developing genome research technologies in Russia........................ 18 
2.1.4 Highly skilled specialists ...................................................................................... 19 
2.2 Economic factors of influence on the market............................................................... 20 
2.2.1 Russian economic crisis ...................................................................................... 20 
2.2.2 Feature of health system financing ...................................................................... 21 
2.3 Political factors of influence on the market .................................................................. 22 
2.3.1 The modernization program ................................................................................. 22 
2.3.2 Sanctions and import substitution ........................................................................ 22 
2.3.3 Tender (auction) regulation .................................................................................. 24 
2.3.4 Features of production localization ...................................................................... 25 
2.3.5 Registration ......................................................................................................... 26 
2.4 Social factors of influence on the market .................................................................... 28 
2.5 Russian market review ............................................................................................... 28 
2.5.1 Market of equipment and materials ...................................................................... 28 
2.5.2 Service commercial market .................................................................................. 29 
2.6 PEST matrix and theoretical statements ..................................................................... 30 
3 APPLYING QUALITATIVE METHODS IN ANALYZING PROSPECTS 
OF GENOME RESEARCH MARKET ....................................................................................... 34 
3.1 Comparison and choice of research methodology ...................................................... 34 
3.2 Secondary data collection ........................................................................................... 35 
3.3 Primary data collection ............................................................................................... 39 
3.3.1 Experts’ interview ................................................................................................ 41 
 
 
4 
 
3.3.2 Sales staff interview ............................................................................................. 45 
3.3.3 General public survey .......................................................................................... 47 
3.4 Methods of analysis .................................................................................................... 49 
3.4.1 Secondary data analysis ...................................................................................... 49 
3.4.2 Qualitative Content analysis ................................................................................ 50 
3.4.3 Statistical Survey Analysis ................................................................................... 52 
4 EMPIRICAL ANALYSIS OF THE GENOME RESEARCH MARKET .................................. 53 
4.1 Analysis of the market and trends through tenders and registration system ................ 53 
4.2      Analysis of primary information ................................................................................... 59 
4.2.1      Summary and results of experts’ interview ........................................................... 59 
4.2.2 Summary and results of general public survey ..................................................... 64 
5 RESULTS AND DISCUSSION ........................................................................................... 67 
5.1 Prediction of genome research on Russian market ..................................................... 67 
5.2 Factors of influence on genome research development in Russia .............................. 68 
5.3 Determination of genome research demand ............................................................... 72 
5.4 General results and suggestion to Case Company ..................................................... 74 
6 CONCLUSION ................................................................................................................... 76 
6.1 Description of the conducted research ........................................................................ 76 
6.2 Suggestions for further research ................................................................................. 77 
List of figures ............................................................................................................................ 79 
List of tables ............................................................................................................................. 79 
List of graphs ............................................................................................................................ 80 
REFERENCES ......................................................................................................................... 81 
 
  
 
 
5 
 
1 INTRODUCTION 
Science and technology development in modern life occupies an important place in all 
areas of people’s activity. Especially it applies to the medical sphere, which is the most 
important for the person and his life. In medical field in the world have begun to develop 
personal genomics - as a science and as a field service niche for business and start-
ups. Traditionally, doctors base their findings on observations, including on the 
symptoms of diseases. However, traditional methods are not always the most effective, 
since each patient has unique genetic characteristics. The opportunities that have 
emerged from the development of medical genetics have made it possible to 
understand in more detail the influence of genetic features and factors on disease 
processes. (Ku, Loy, Salim, Pawitan, Chia 2010, pp. 403-415.) Genomics section 
associated with the sequencing and analysis of the human genome. 
Definitely it is a trend towards the development of this area, but at the cost of 
technology development and appropriate equipment is quite expensive. In Russia there 
are a lot of Special Institutes and scientific centers which have studied topic of genetic, 
but in usual hospitals and clinics such test are rather seldom or quite expensive. So 
many commercial companies are not engaged in this direction, because it is not clear 
when these tests will have a mass character in Russia and will be able to generate real 
profit (Suvorova 2015). 
The task of medical genetics is to identify, research, prevent and treat of genetic 
diseases and the ways to prevent the harmful effects of environmental factors on 
human heredity. 
Last several years in Russia has been a policy of import substitution, and government 
encourages the development of domestic production. In Russia have started a lot of 
manufacturers, some foreign factories are moving their production to Russia in order to 
avoid the loss of the Russian market. (Timoshenko 2015.)  
Area of Genetic medicine and in particular the study of the genome is the most 
important milestone for the public health application of genomics and genetics, 
decipherment of the human genome. However, this topic is not fully researched the 
present day. Brought to a fairly substantial overall picture of the human genome 
structure and the role in it of nucleotides, their sites and sequences, their functions and 
interactions. Due to deciphering the genome it has become much easier and cheaper to 
 
 
6 
 
detect a tendency of various diseases, both hereditary and non-hereditary (Phillip & 
Pavel 2010). 
From the viewpoint of science, the topic is deeply interesting and has a great future. 
Genome Research is widespread in the USA and is part of the insurance program. But 
such studies are rather expensive and in Russia from a commercial point of view, are 
not yet widespread. But from another side Market genome-sequencing in Russia 
annually increases an average of 15%. For research information on 2016 the market 
volume is estimated to be more than 2.5 bln. Rubles. (Yashina & Malacho 2015, pp.49-
55.) 
Case company has idea to develop this area and they started to collect information and 
market research of equipment, technologies and test systems for Genetic medicine. But 
there are questions whether be interesting from commercial side. If only few tests are 
made in this area daily, there will be no real market for such equipment and devices. 
1.1 Case company 
Case company Corwаi LTD. is situated in Russia and at the moment is official sales 
distributor of foreign manufactures of medical devices and equipment from China, 
Estonia, Poland and Italy. Main area of company activity is laboratory and diagnostic 
area of medicine. The head office is located in St. Petersburg; also the company has 
subdivisions in Moscow.  
The company is engaged in complex supply of equipment and medical devices in state 
and private laboratories; mainly it is biochemistry, hematology, urine analyzers and tools 
for the collection and storage of samples of biological materials, such as vacuum blood 
collection tubes, automatic lancets for getting capillary blood, containers for urine and 
other products.  
Sales policy is the following: 
 Direct sales in hospitals and clinics in Moscow and Saint-Petersburg (through 
tenders or direct contact with medical institutions); 
 Distribution network in regions of Russia. In Figure 1 is available the distribution 
geography of the distribution network of Case Company.  
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Figure 1. Geography of Corwаi’s distribution network 
Not so long ago the company began to develop additionally the sales of polymerase 
chain reaction (PCR) equipment, reagent sets and materials. Company start this 
direction as sales distributor of foreign manufacture, but have their own manufacturing 
possibilities to follow this project as local Russian manufacture for get preferences from 
Russian government. 
The direction of PCR is also based on the study of the DNA of the human. It is a high-
precision method of molecular genetic diagnosis that allows identifying a variety of 
infectious and hereditary diseases. PCR is a method that allows finding a small piece of 
genetic information (DNA) of an infectious agent, various malignant neoplasms and the 
definition of genetic to various diseases in the clinical material under investigation and 
multiplying it multiple times. Amplifying DNA during few hours can make identification 
and multicasting of a certain DNA sequence in billions of times. (Garibyan & Avashia 
2013, pp. 2-4.) 
PCR research is a popular and relatively cheap method in Russian market and used 
widely for infectious determination, such as HIV, Tuberculosis, Chlamydia and other. In 
the field of diagnosis of cancer, PCR research makes possible to establish a diagnosis 
at an early stage of the disease, to estimate the prognosis, and subsequently the quality 
of the therapy. According to the company's observations in the Russian market 
American and local Russian manufacturers widely distribute equipment and reagent 
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kits.  
But PCR research method allows only to compare a person's DNA with a primer - that 
is, a causative agent, and tell whether there is a coincidence or not. Many tests are 
performed only with a response yes or no; some provide quantitative indicators of the 
"pathogen" in human DNA. An all-round understanding of the human genome and its 
peculiarities allows doing more complex genome sequencing technologies. 
1.2 The general essence of the method of genome research 
Genetic analysis of DNA is a study of the human genome for diagnosing and 
determining the individual risk of developing diseases and the tolerability of drugs, as 
well as for obtaining data on genetic characteristics, inclinations and abilities of a 
person. Each person has a unique set of genes (genotype), which determines his 
individuality and predisposition to a particular disease. (Ershov 2015.) 
During the sequencing of the genome (or genome research) a researcher or clinical 
specialist receives information about all DNA which was found in the 23 chromosomes 
of human cells that contain about 3 billion pairs of nucleotides. This information includes 
sequences of all genes (20,000) and non-coding regions (which constitute the largest 
part of the human genome and participate, in particular, in the regulation of gene work, 
but the functions of the noncoding portion of the genome are still to be determined). 
Thus, as a result of one study (sequencing) of the genome, it is possible to obtain a 
huge array of information that will be used in clinical practice, both with the already 
available data, and with the data that scientists will receive as scientific progress in the 
future. (Sukchev 2013.) 
1.3 Objectives of the study 
Main aim of this Master’s Thesis is to understand how genome research will develop in 
Russia on macro level and how it will be interesting from the standpoint of commercial 
activity. The main indicator is the number of tests that will be carried out with the 
exception of factors of external influence and the quantity of equipment that is used for 
such tests. The findings of this research will allow the company to make a decision 
about the feasibility of investments and time in this area for business development. 
Research question: forecasting of demand of Genome Research on Russia market 
from commercial point of view. 
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Sub questions: 
 What are conditions of the market: demand, customers, competition and other 
business environment factors? 
 Political and economic forecast for Genetic Medicine in Russia and law 
regulations. 
 Customers’ opinion about the potential product and prospects of it on the market 
from various angles. 
 Knowledge, expectations and readiness of ordinary people for the topic of 
genome research. 
 The ability for Case Company to promote a new product through an existing 
network of distributors. 
1.4 Definition of products for research  
The study of the genome is worthy of an abstraction topic, which includes 
methodologies, scientific developments and practical use. Case company is primarily a 
trading and manufacturing company that works directly in the market of sales products.  
In this part it was defined products which are used for Genome research for medicals or 
research aim and can be produced and sold in reality.  
The human genome consists of more than three billion of these nucleotides, which are 
located in a strictly defined sequence. Unfortunately, sometimes it happens that some 
nucleotides disappear or are doubled or replace one another. In many cases, this leads 
to an incorrect formation of the human health. This can manifest as congenital 
malformations or small developmental abnormalities, mental retardation, autism or other 
manifestations. (Nikolaenko 2012.) 
Sequencing is a test for determining genetic damage (mutations) in DNA, which are the 
cause of hereditary diseases, hereditary predispositions or the peculiarity of the 
organism. 
Determining the structure of the genome is not an easy task. It requires the isolation of 
DNA, its special processing (fragmentation, modification, amplification) and obtaining 
information on a special device - a sequencer. Full-genomic sequencing gives the most 
 
 
10 
 
complete set of data on the structure of genetic material and allows us to evaluate in 
detail all individual genetic variations. (Nikolaenko 2012.) 
Products that are used for genome research begin with simple devices for collecting 
samples, equipment for DNA isolation and end up with IT systems for analyzing and 
outputting results. In the framework of this study, it will not consider products of general 
use, for example tubes for taking blood – because they can be used for other medical 
test too. The goal of this research will be precisely the sequencing of the genome. So it 
considered as products  sequencers and reagents for them. 
1.5 Phenomenon of the thesis topic 
The topic of creating a new or innovative product is widely studied and described in 
books and researches. This information can be used for following study. From the other 
side there are a lot of researches of development areas in medicine in local and 
international sources. Usually these studies have scientific nature. Feature of this study 
will be to identify research scientific trends and make comparisons with real 
opportunities for manufacturing or possibilities for sales market. 
Also the research should take into account the features of the local market. Because 
some product which is used, for example, in rich and modern European countries or the 
USA may not be interesting for Russian market. 
The Thesis relates the perspectives of science development and the real possibilities of 
demand in this area for making decision about investment in the Genome Research 
direction. There is available information from the standpoint of scientific research 
institutes and from the standpoint of large companies already involved in Genetic areas, 
and as usual they said that it is a very perspective and in future there will be large 
demand.  
But during speaking with practical doctors or visit some medical exhibitions there is little 
information about such products and the present Russian market relates to this topic as 
a far and expensive prospect. So the main goal is to compare the real possibilities of the 
market demand and scientific perspectives for a decision to participate in this direction 
or not. 
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1.6 Delimitations of the study 
The study will include following points: 
 Theoretical part based on the market research of new directions and tendency 
of development of Genetic medicine; 
 Empirical part based on practical research, which will follow: 
- To analyze current market situation and possibilities of development; 
- To collect and analyze data from specialists. 
The research will give recommendations for future research and economical calculation 
of the projects. This part will not be included in this study. But it will include first 
marketing review of market and tendency. 
The Thesis will not include the research of Genetic and Genome topic as a scientific 
topic, there will be a short review of base technologies which are going to be analyzed 
as “product”. 
The Genome research is carried out for the purposes of scientific research and samples 
can be taken not only from human biomaterials but also from animal, micro-borders and 
other. This Thesis will focus only on the human genome and its capabilities for research 
for medical purposes. 
1.7 Structure of the thesis 
In the first part, there is a description of the problem, the objectives of the research and 
a brief introduction to the essence of the study of genome test and description of the 
tasks of the Case Company in this work. 
In second part is the macro environment analysis on the base of PEST (political, 
economic, society, technology) model of the international market, the current situation 
on the Russian market and it reveals the factors of influence on demand in the genome 
sequencing market and theoretical market forecasts. On the base of theoretical 
background are formed theoretical statements, which are later verified on the basis of 
an empirical analysis.   
The third part describes the methodology for analyses, with a breakdown into the 
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analysis of secondary information and primary information. A methodology for collecting 
information from different groups of respondents and ways to analyze this information is 
also described. 
The fourth section describes the results of the analysis of information using the 
indicated methods and the main results are laid out. 
The fifth part is the formation of the author's conclusions on the basis of the analyses 
and forecasting of the market of sequencing based on the theoretical information and 
the data obtained from the empirical study. 
In the sixth part, the author summarizes the results of the entire study, indicating the 
Company's recommendation on the tasks assigned, as well as recommendations on the 
possibilities for future research. 
2 MACRO ENVIRONMENT ANALYSES  
Today's business has reached a fairly high level of development, where priority is given 
to monitoring those factors that have a great impact on the successful development of 
the company. One of the main methods that are now used is the PEST analysis (Figure 
2). This type of analysis is a marketing tool designed to identify the political, economic, 
social and technological aspects of the external environment that affect the company's 
business. (Bensoussan & Fleiser 2008, pp.161-177.) 
For the study of factors that affect the market of genomic research will be made a 
complex analysis of external factors that affect the activities of business entities in this 
fields. The title itself contains the main areas that are being analyzed: politics, 
economics, society and technology. 
The analysis is carried out according to the "factor-enterprise" scheme. The results of 
the analysis are formulated in the form of a matrix, which is subject to macro-
environment factors; the predicate is the force of their influence, estimated in points, 
ranks and other units of measurement. The results of the PEST analysis allow us to 
assess the external economic situation in the sphere of production and commercial 
activity. (Basu 2004 pp.98-101.) 
In this Thesis, the result of the PEST analysis will be evaluated in a text evaluation of 
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the influence of the factor, after a theoretical review and verification of theories based 
on the empirical research. 
 
Figure 2. Structure of PEST analysis. (Bensoussan & Fleiser 2008, pp.161-177.) 
 
2.1 Technological factors of influence on the market 
2.1.1 Basic history of genome sequencing 
The first method of sequencing, which scientists managed to use to process whole 
genomes (including the human genome), was sequencing by Sanger (Sanger 
sequencing) in 1977. For more than 30 years, until the 2000, it remained the main way 
to determine the sequence of any nucleic acid: it was this method (with minor 
modifications) that the human genome was read. (Obenrader & College 2003.) And until 
now, Sanger sequencing is the most accurate method, which is used to check the 
results of a new generation of sequencing if necessary. This method was used in global 
projects for sequencing the human genome, various animals, bacteria and viruses. 
However, this method was not suitable for rapid routine sequencing of human genomes 
for clinical purposes. Therefore, there was a need to invent new technologies for full 
genomic sequencing. 
In 1990, the international program "Human Genome" was launched, in which separate 
sections of the pre-tagged genome for sequencing were isolated for each team from 
America, Europe and Japan (Speaker, Lindee & Hanson 1993 pp. 18-19). By this time, 
PEST 
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several biotech companies, primarily Applied Biosciences, have learned to automate the 
sequencing processes of Sanger. One of the first who realized the possibilities of 
automation of sequencing was Craig Venter. In 1992, two years after the launch of the 
Human Genome Project, Venter organized his own institute (The Institute for Genomic 
Research), in which DNA sequencing was first put on stream. (Fridovich-Keil 2016.) 
The cost of sequencing of both individual genomes by the time they were read in 2007 
was about one million dollars. And this, of course, is significantly lower than 100 million 
in 2001, but still a lot: with such prices count on reading the genomes of hundreds or 
thousands of people or offering such a service to ordinary people would be impossible. 
(Muir, Li, Lou, Wang, Spakowicz, Salichos, Zhang, Weinstock, Isaacs, Rozowsky & 
Gerstein2016, pp. 3-4.) 
However, fortunately, just at the moment when the reference genome was created, the 
technology that allows to "catch" individual differences in genomes is fundamentally 
simpler and cheaper than usual sequencing technology of DNA microchip (Johnson 
2009). DNA microchips began to appear in scientific laboratories in the 90's, and in the 
mid-2000s the first companies appeared that offered analyses of the personal genome 
on their basis. 
Today the genotyping technologies are losing their positions (speed and cost) and the 
era of the so-called new generation sequencing methods is starting. It is their 
appearance that has ruined the cost of the procedure from millions to thousands of 
dollars. (Ershov 2015.) 
2.1.2 The technological development of genome research on international market 
Full genome sequencing technology revolutionized medical diagnostics, academic 
laboratories and biopharmaceutical companies, and changed the structure of healthcare 
and applied markets. 
In the USA sequencing has become a real sector of the economy, in a direct or an 
indirect form it involves about 300 thousand people. There were launched genomic 
projects in 2014, January 2015 and the US president proposed to allocate $ 215 million 
from the 2016 budget on the project of sequencing a million genomes of US citizens. 
(Yashina & Malacho 2015, pp.49-55.) 
In the United Kingdom at the end of 2012, Prime Minister David Cameron presented the 
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"Strategy for UK Life Sciences - One Year One" program, which formulated a goal - to 
make the UK the world leader in genomics and bioinformatics. It details the main 
expected results and measures that the Government will take to achieve this goal. One 
such measure was the allocation of £ 100 million for the sequencing of 100,000 
genomes of cancer patients and other patients. (Zubov 2012, pp. 2-15.) 
In China in Beijing is also organized one of the most powerful centers of full-genomic 
sequencing. In 2017 the largest center for genetic research in the world, the Beijing 
Institute of Genetics (BGI), has announced the opening of two laboratories in the United 
States, which will be engaged in an ambitious project to create next-generation 
sequencing technology. China will try to get more efficient sequencing technology 
through cooperation than the one developed by the leading American company in this 
field “Illumina”. (Cyranoski 2016, pp.462-463) 
In 2013, a new player from Saudi Arabia started a national network of sequencing 
centers for carrying out genomic sequencing of one hundred thousand of its citizens. 
(Zubov 2012, pp. 2-15.) 
According to a report by Grand View Research, Inc., the genomics market in the world 
is estimated to reach USD 22.1 billion by 2020. The expected growth of market is 10.3% 
from 2014 to 2020. (Grand View Research 2016.) 
In the last decade, sequencing technologies have developed at a very rapid pace, thus 
reducing the cost of each DNA base. Sequencing, which cost $ 3 billion a decade ago 
for the Human Genome Project, can now be done for thousands of dollars or less. 
(Gitschier 2010.) The first devices for sequencing were created, first of all, for scientific 
research. They had a reasonably low throughput and were not suitable for clinical 
studies. At present, platforms for DNA sequencing of the "third generation" have 
appeared and are actively developing. The third generation differs from the second in 
that the primary amplification of DNA is no longer required. The DNA under study is 
sequenced directly at the level of one molecule using specially designed polymerases. 
The advantage of this approach is that it is possible to avoid the problems associated 
with the accumulation of errors arising during the amplification of DNA. (Sukchev, 
2013.) 
In following Table 1 are noted major market players with short description:  
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Name of company Country Description of company 
Illumina Inc., 
 
USA Illumina, Inc. founded in April 1998, 
develops, manufactures and implements 
systems for analyzing genetic diversity and 
biological functions. Illumina produces a line 
of products and services for sequencing, 
genotyping and studying gene expression to 
carry out genetic studies necessary for 
medicine, genomics and proteomics. 
(Illumina) 
Oxford Nanopore 
Technologies 
 
United 
Kingdom 
U.K.-based company founded in 2005 and is 
developing and selling nanopore sequencing 
products for the direct, electronic analysis of 
single molecules. (Oxford Nanopore 
Technologies) 
Roche Diagnostics 
 
Switzerland 
USA 
Roche is one of the leaders in the healthcare 
market, one of the ten largest companies in 
the world in the field of pharmaceuticals and 
diagnosis of diseases. The main goal of 
Roche is the production and promotion of 
drugs developed on the basis of innovative 
technologies. The company was founded in 
1896 in Basel, Switzerland, and today has 
offices in more than 150 countries and 
employs more than 70,000 people. (Roche) 
Roche Holding AG buys up companies and 
research centers in the field of medicine and 
has a very wide profile of activity from gene 
equipment to medicine drugs. (Roche) 
Bio-Rad Laboratories 
Inc., 
USA Bio-Rad Laboratories is a large manufacturer 
of analytical equipment, auxiliary devices 
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 and consumables for various biology and 
clinical laboratories. The company is 
constantly improving in the development of 
new devices. The producer achieved special 
achievements in the field of genetics. Under 
the Bio-Rad logo a whole line of devices for 
PCR, electrophoresis, proteomic analysis, 
gene transfer, including using the 
transfection method, is offered. (Bio-Rad) 
Thermo Fisher Scientific  
Applied Biosystems™ 
 
USA Thermo Fisher Scientific is an American 
multinational biotechnology product 
development company, created in 2006. 
Applied Biosystems (formerly NASDAQ: 
ABIO) is the original name of a 
biotechnology company founded in 1981 in 
Foster City, California, which was joined to 
the Thermo Fisher Holding. 
(Thermo Fisher Scientific) 
Beijing Genomics 
Institute 
 
China The scientific center dedicated to 
determining the genomic sequence, 
headquartered in Shenzhen, Guangdong 
Province, China from 2008 year. 
(Researchgate) 
Table 1. Major international players of genome research market 
From the main review America holds the leading positions in the market of commercial 
sequencing. Also when studying the history of companies that are engaged in research 
in the field of sequencing and genomic development, it is interesting that companies are 
often change within the market – some famous companies bought up by large holdings.  
For example, in 2010 Life Technologies Corporation acquired Ion Torrent, which 
developed semiconductor sequencing technology, for $ 725 million. In 2013, Termo 
Fisher Scientific Corporation acquired Life Technologies with all of its assets for $ 13.6 
billion. The structure of the supply market is changing very rapidly, both in terms of the 
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technologies offered and the companies themselves, and the data very quickly become 
old. 
Very instructive is the story of the company 454 Life Science Inc. that acquired 
corporation Roche. In 2005 – 2007 it was the best in the world pyro-sequencers 
company but did not withstand competition and in the middle of 2014 year was 
withdrawn from production. Approximately at the same time, the development of the 
Chinese pyro-sequencer BIGIS-4, which in all respects was not inferior to the Roche, 
was completed, but appeared too late. (Zubov 2012, pp. 2-15.) 
In 2017, several promising developments in the field of new generation sequencing are 
presented on the market. These approaches are applied in sequencers of a new 
generation:  
 Ion Proton and Ion Personal Genome Machine (Thermo Fisher Scientific) - 
technology of ionic semiconductor sequencing;  
 MiSeq and NovaSeq (Illumina) - a technology for sequencing on molecular 
clusters using fluorescently labeled nucleotides;  
 MinION, GridION X5, PromethION and SmidgION (Oxford Nanopore 
Technologies) - nanoporous sequencing. 
2.1.3 Features of developing genome research technologies in Russia  
In Russia, the development of NGS (next generation sequencing) technologies until 
recently was considered an impossible task due to the lack of experience in carrying out 
such applied works and limited financial possibilities. But at the same time in Russia the 
geography of attempts to develop sequencers of a new generation is very wide and 
includes: 
 Moscow (LLC "Sintol", LLC "Rastr Technologi", LLC "Helicon Company", IMB 
RAS, etc.),  
 Novosibirsk (IAE SB RAS, IHBMM SB RAS, IFP SB RAS, LLC "Biosset"), 
 Zelenograd (OOO Gamma, LLC ElemInfo ", LLC" NANO VIZHIN ", JSC" NT-
MTD ",  
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 St. Petersburg (IAP RAS,OOO NPK "Orion Medik"),  
 Protvino (LLC "NPO DNA-Technology"), 
 Vladikavkaz (LLC WTC "Baspik"),  
 Irkutsk (LIN SB RAS), Ufa (IBG UNSC RAS / OOO Biofort),  
 Krasnoyarsk (IIPiRE / OOO Vitim-LAB),  
 Chernogolovka (ISSP RAS),  
 Dolgoprudny (Carbonlite LLC), 
 Saratov (SSTU) 
In 2013, due to financial support from the Ministry of Education and Science of the 
Russian Federation and the Technology Platform "Medicine of the Future", the Institute 
of Analytical Instrumentation of the Russian Academy of Sciences, LLC "Sintol" and the 
Experimental Plant for Scientific Instrument Making of the Russian Academy of 
Sciences created the first Russian sequencer "NANOFOR 05". It is an open automatic 
capillary electrophoresis system with detection of laser-induced fluorescence. 
Technology which uses this analyzer is capillary and near to “Sanger sequencing” which 
was the founder of sequencers (Arustamova 2015, p.31.). 
Despite the fact that this technology has already lost to sequencers of the second and 
third generation, this is widely used in the Russian market and in the world and there 
are a number of tasks that are solved with the help of these sequencers. According to 
experts, the Russian market of sequencers’ potential is no more than 1000 sequencers. 
The number of capillary sequencers is 85% of the total volume and is 200 000 - 300 000 
analyzes per year. (Arustamova 2015, p.31.) 
2.1.4 Highly skilled specialists 
After the procedure for sequencing the genome, it is not available finished result but get 
a set of data that must be interpreted; decipher made by the biologists; interpretation 
made by bioinformatics. Biologist specialization is popular in Russia and there are a lot 
of such specialists. But the most difficult work is just the second - bioinformatics need, 
on the one hand, to know biology, on the other - programming. They have to decode the 
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genome, and it is difficult to find them: an ordinary programmer is hard at mastering 
molecular biology and vice versa. Professionals in this field will play a major role in the 
personalized healthcare practice because they are responsible for managing patient 
data. (Alzu’bi, Zhou & Watzlaf 2014, p.3.) 
Figure 3 shows the sample of result of sequencing the genome using BrightDye (A), 
Bigdye (Б), which were provided by researchers from the Institute of Cytology and 
Genetics of the SB RAS, Novosibirsk and published in article “Reagents for sequencing 
by Sanger and much more from Nimagen in the 2015” on web site of Skygen company 
(Skygen). 
 
Figure 3. Sample of results from the genome sequencing 
Results of the system do not give us a ready result with a description of the genome, of 
all the particular systems of man, his predisposition, and so on. Sequencing gives the 
specialist a set of "code" that must be interpreted with the use of high qualification.  
2.2 Economic factors of influence on the market 
2.2.1 Russian economic crisis 
In connection with the Russian economic crisis of 2015 expenditures of the budgetary 
sphere are significantly reduced. The law on the budget, presented by the Ministry of 
Finance of the Russian Federation, assumes a drastic reduction in spending on health 
in 2017. Thus, in 2017 the government reduces medical expenses in comparison with 
2016: in the specified budget of 2016 there was five hundred and forty-four billion rubles 
are spent for this purpose, then for 2017 only three hundred and sixty two billion rubles 
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will be allocated for same. From this “medical” budget money is going to send around 
sixteen billion rubles for medical research sector, which is a decrease compared to 
2016 by 21%. (Obukchov 2016.) 
2.2.2 Feature of health system financing 
System financing health care area in Russian federation can be represented in the 
following Figure 2 created by the author. 
 
 
 
 
 
 
Figure 4. Financing of the health system sources in Russian Federation 
The main newest challenge for the Russian healthcare system is the need to address 
the large-scale tasks of reducing the death rate and increasing the salaries of medical 
workers while reducing the size of government funding. 
The most significant institutional changes in the sphere of health in recent years are 
associated with the modernization of the mandatory medical insurance (MMI), carried 
out in 2011-2015  in accordance with Federal Law No. 326-FZ of November 29, 2010 
"On Mandatory Medical insurance in the Russian Federation". As a result of the 
restructuring of the compulsory medical insurance, there was a stabilization of financial 
flows in this system. In addition it is important that in different regions of Russia the 
nature of financing is very different. (Shishkin, Sazina & Selezneva, 2015, pp. 3-15.)  
Despite the general trend towards strengthening the role of MMI in public health 
financing, there are still very large differences between regions. Moscow and Saint-
Petersburg are historically the richest regions in Russia on budgetary financing and on 
the level of the overall economy. Legal entities pay taxes at the place of their 
registration. Many corporations in Russia, whose production activities are almost 100% 
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concentrated in the regions - nevertheless, have central offices and are registered in 
Moscow. Accordingly, all of their gigantic incomes, even taking into account optimization 
and tax evasion - still settle in a fair amount in Moscow for example.  
Indeed, the main reason that Moscow and Saint-Petersburg have a solid budget is 
because of the tax component. The remaining regions are often financed from the 
federal budget, which is formed at the expense of donor cities. The regions-donors for 
2016 became: Moscow, Moscow region, Leningrad region, Republic of Tatarstan, 
Sverdlovsk, Chelyabinsk, Tyumen regions, Nenets Autonomous Area, Khanty-
Mansiysky Autonomous Area and Yamalo-Nenets Autonomous Area (Ivanov 2016). 
2.3 Political factors of influence on the market 
Policies and projections at the macro level in any case affect economic situations and 
micro-level behavior for specific companies and individuals. When starting a project, it is 
important to take into account not only internal indicators and metrics, but also analyze 
the opportunities and risks associated with the country's behavior in domestic policy and 
relations with other countries. 
Now Russia is in a difficult and interesting situation because of the sanctions and the 
attitude of Europe and America. On the one hand it is bad, but on the other hand such 
situation has given opportunities for the development of some business in Russia. 
(Lipman & Petrov 2010.) 
2.3.1 The modernization program 
In 2011 in Russia was in operation state modernization programs of the Ministry of 
Health. Many laboratories purchased equipment in 2011-2012 of which now many are 
outdated and their least exploitation is not favorably. Thus, the equipment fleet in 
Russian institutions is outdated in terms of technology and also the cost of research. 
New developed equipment and devices allow making technology of genome research 
cheaper. The cost of sequencing the same amount of material at the second and third 
generations differs at times. As a result, all previously purchased by Russian centers 
sequencers of this series have aged both morally and economically. 
2.3.2 Sanctions and import substitution 
The sanctions imposed on Russia by a number of Western countries, and the Russian 
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government's response, have had a stimulating effect on import substitution in the 
economy. Import replacement in 2017 is within 30%, which means that all goods, 
products, as well as services produced in Russia, account for only 30%, the rest has to 
be bought abroad. By the end of the year, this figure may decrease, but not due to an 
increase in the production of domestic goods, but due to a decrease in imports, which 
will lead to the formation of a deficit in the country. (Aris 2017.) 
According to analysts' forecasts, the most promising sectors for import substitution at 
the moment are: 
 Machine-tool construction; 
 Heavy engineering; 
 Textile production; 
 Electronic industry; 
 Medical production; 
 Pharmaceutical production; 
Perhaps nowhere has the idea of import substitution caused so much concern, as in the 
field of medicine. Under the sanctions introduced in 2014 were more than 100 different 
positions, from medicines to specialized medical equipment. But a lot of drugs, 
diagnostic equipment and other things were almost completely provided with goods of 
foreign production. 
Today, the state program of import substitution in the medical sphere includes more 
than 200 projects, most of them already developed. Only in 2016 in support of 
manufacturers about 15 billion rubles were allocated from the budget (Neverova 2016).  
To stimulate production, free special economic zones (SEZ) are actively developing. 
The world's largest experience in the creation of the SEZ belongs to European 
countries. Special economic zone is a territory that has a special legal status, on which 
preferential economic conditions for the performance of activities for Russian or foreign 
entrepreneurs operate. Residents of such zone have special tax conditions, custom 
clearance conditions, land infrastructure (water, electricity connection) and low cost of 
land purchase. But in order to be located in such a zone it is necessary to prepare a 
 
 
24 
 
business plan for the project, protect it and get state support. (Schneider 2015, pp.4-6.) 
Russia has a serious potential for the operation of SEZ, which now has 25 such zones 
in different directions. For production of medical product it can be applied: 
 6 industrial special economic zones (SEZ PPT Alabuga, Togliatti, Lipetsk, 
Mogilino, Titanium Valley, Lyudinovo); 
 5 technological zones (SEZ TVT Dubna, St. Petersburg, Zelenograd, Tomsk, 
Innopolis). 
2.3.3 Tender (auction) regulation 
In addition to stimulating domestic production through funding and project grants, the 
Russian government also applies restraining measures. Federal Procurement Law (44-
FZ) and Resolution No. 102 list medical products, which were manufactured in foreign 
countries that may not be bought by state-owned companies if at the same time at least 
two equivalent domestic medical products are offered. When making purchases of 
medical equipment, devices or reagents through state tender if an application there is 
more than two offers of “domestic” manufacturers ("domestic" goods means goods 
which are produced in Russia, Belarus, Kazakhstan, Armenia, Kyrgyzstan) foreign 
goods cannot take part in this tender.  If in the auction there are one “domestic” and a 
foreign participant, the tender will go in usual way but if the winner is a participant who 
offered goods of foreign origin in the application, then the contract is concluded at a 
price 15% below its price offer. For example, a participant who offered a price of 1 
million rubles during the auction, but if a product of foreign origin is offered in the bid, 
the contract will be concluded at a price of 850 thousand rubles. (Heidemann 2016.) 
These laws have strongly influenced the purchasing market in Russia. The market of 
medicine services in Russia is overwhelmingly composed of state in comparison with 
commercial centers. For example, in 2016 Case Company made a research about 
market of vacuum blood tubes which are used in laboratory and compared the share of 
state buyers and commercial and concluded that 80% of all purchases are made by 
public tenders and only 20 % by private clinics. 
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2.3.4 Features of production localization 
In these conditions, Russian companies began to move the place of production from 
abroad to Russia. In the early years there was a very interesting trend - while the 
Russian government did not fully determine the criteria for localizing production many 
companies brought the product from abroad and made a very small part of the 
technological processes in the territory of the Russian Federation and claimed that it is 
“domestic” product.  
The Russian government is discussing the possibility of modernizing the domestic 
economy, pursuing a policy of import substitution through localization, which means the 
placement of production in the territory of the Russian Federation originally of foreign 
origin. 
For medical products were established criteria for recognition of products localization: 
 The share of imported components in the final cost of a medical device should 
not be more than 50%. 
In addition, it is necessary to ensure: 
 The required volume of technological operations 
 The presence of rights to technical / engineering / engineering documentation in 
the amount sufficient for production, modernization and development related 
products 
 Requirements for development or design 
 Requirement of availability of service 
To confirm these requirements, company should receive a certificate CT1 in the 
Chamber of Commerce on a fee basis. (Chamber of Commerce of the Russian 
Federation) 
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2.3.5 Registration  
Equipment and devices for genome research can be used in several directions: 
 clinical practice 
 research activity 
If equipment is used for clinical practice, it is medical product. All medical products 
(equipment, devices, reagents, software) traded on the Russian markets should be 
registered in Roszdravnadzor - The Federal Service for Supervision in the Sphere of 
Social Development and Health, which is an executive body whose main task is 
supervision and control in the field of health and social development. This registration 
must be obtained regardless of where the equipment is used - in public hospitals or in 
private clinics. Registration of foreign products will also be checked during customs 
clearance when imported into the country. For state hospitals and tenders products 
without registration will not be allowed in the tender. If the private clinic uses the 
products without registration, then Roszdravnadzor has the right to inspect and issue 
significant sanctions right up to criminal prosecution. (RF Government Resolution from 
December 27, 2012 N 1416, 2017). 
If the genome tests are made for research activity, then, on the one hand, the 
requirements are slightly weaker, but laboratory (or institute) should have status (and 
resolution) of scientific and research Institute. In this case, the tests cannot be applied 
to medical purposes, but only as research and have a recommendation character. 
The issue of registration of medical products is now very acute in Russia.  By 
experience of Case Company, for last 3 years the procedure for registering a medical 
product - even the simplest one - takes from 1 to 2 years. These terms include the 
preparation and updating of the product dossier, the conduct of toxicological and clinical 
test and documentary procedures. In case of refusal at some stage, even because of a 
small error in documents, files and papers, company can roll back several stages and 
increase the registration time. According to the companies’ feedbacks in the Russian 
market, the problem of registration concerns not only foreign manufacturers, but also is 
similar for local manufacturers.  
There are also problems in the registration of high-tech products, such as the product 
considered in this Thesis. Usually, clinical trials are conducted in comparison with 
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products already registered in the market and an assessment of compatibility is made. 
When registering a fundamentally new product, additional difficulties arise in the 
methods of evaluation and the methods used - which only delays the time of 
registration. (Astapenko & Sukhanova 2016.) 
Questions from representatives of the professional community also cause insufficient 
number of experts in the country who are able to understand the specifics of the whole 
range of medical equipment; term of waiting for a response when submitting documents 
for registration of medicinal products; the need to maintain a staff of highly qualified 
technical staff who deal exclusively with registration issues of medical product; the 
incommensurably high costs of registration – around 600 000 rubles for one item, from 
which the smallest enterprises suffer most, which because of this are forced to cease 
their activities. (Denanova, Vilensky & Agups 2014). 
As it is clear from the chapter about the description of sequencing technologies, these 
technologies are developing very rapidly and the equipment is rapidly becoming 
obsolete - it is possible that while the company registers two years the equipment and 
reagents, sequencing technologies will go ahead and registered analyzer in two years 
will be already obsolete.  
So the development and modernization of medical facilities are largely constrained by 
the administrative barriers. This question often and actively rose at many thematic 
conferences. In August 2017, the first meeting of the working subgroup on the 
development of high-tech medical products of the expert council for the development of 
biotechnology, pharmaceutical and medical industry was held at the State Duma 
Committee on Economic Policy, Industry, Innovative Development and 
Entrepreneurship. Experts suggested simplifying the rules for registering medical 
products. (Zdrav.expert, 2017.) 
Participants of the meeting came to the conclusion that the introduction of international 
practice in Russia on the declarative form of confirmation of compliance of medical 
facilities with the required parameters in case it already has a registration certificate 
would help to remove a number of problems when registering high-tech medical 
products. (Zdrav.expert, 2017.) 
All the described factors affect the development of the medical sector in general and the 
development of genomic sequencing in particular and should be taken into account, 
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when predicting the development of this direction in the future. 
2.4 Social factors of influence on the market 
The main deterrent to the active development of Russian genome research market 
(direct-to-consumer) segment is the low awareness of society, the population about the 
modern possibilities of genetics and its accessibility. Many people think that genetics is 
a purely scientific discipline, without any practical significance. The knowledge about 
what opportunities genetics gives in terms of personalized medicine are almost absent 
from medical personnel.  
Therefore, in itself, the genetic test is still an entertaining and cognitive product for the 
premium audience. To translate its effect from entertainment into a practical field, 
consultations of specialized doctors, additional analyzes, recommendations of 
professional nutrition experts and other aspects of the lifestyle are needed. (Rusbase, 
n.d.) 
For research and work with the results of genetic analyzes, their data need to be stored 
somewhere, and today in the world there is an active process of accumulation and 
storage of genomic information in large databases - biobanks. The creation of such 
storage facilities is primarily related to the need to conduct medical research and 
diagnosis of deadly diseases, which require an increase in the scale of the data under 
study (Eropkin 2015). For maximum accurate comparisons, scientists and/ or medical 
professionals need the largest possible base of DNA samples. The social issue as a 
defense has only just begun in Russia. 
2.5 Russian market review  
2.5.1 Market of equipment and materials 
Prospects of the world market are very promising, but Russian market does not look so 
rosy. According to a research in 2015 the market of full genomic sequencing in Russia 
annually increases an average of 15%. At the same time, the market volume is 
estimated at more than 2.5 billion rubles. The main part is the equipment market, the 
volume of the market for consumables is very small and the number of installed high-
performance analyses more than 120 units. (Yashina, Malacho & Sorokoletov 2016, 
pp.182-186.) 
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Researchers Yashina and Malacho (2015) made a study of the market sequencing 
based on government and commercial purchases. In Table 2 is information from state 
trade system about volumes of purchases. 
Year State contract, 
rubles 
Commercial 
orders, rubles 
Total, rubles 
2010 511 162 000 No data 511 162 000 
2011 2 211 566 000 No data 2 211 566 000 
2012 2 509 868 000 87 000 2 509 955 000 
2013 2 135 698 000 187 535 000 2 323 234 000 
2014 2 145 732 000 232 975 000 2 378 708 000 
2015 (6 months) 1 345 843 000 177 091 000 761 467 000 
Table 2. The volume of the Russian market calculated by the amount of contracts 
(Yashina & Malacho 2015, p.183). 
Foreign companies dominate the market, and the composition of has not changed 
during the last few years. The world and the Russian markets are monopolized by 
several large companies (Illumina, Thermo Fisher, Roche, Qiagen), expanding their 
sphere of influence is due to acquisitions of smaller research projects. 
Organizations purchasing equipment are roughly divided by belonging to the Russian 
Academy of Sciences and the Ministry of Health. By geographic principle, the bulk of 
the equipment is in The Central Federal District, Moscow and St. Petersburg, in less 
remote regions (Murakhovsky 2016). 
2.5.2 Service commercial market 
High-performance sequencing methods have been developed since 2006 and allow to 
read the complete human genome in a few days. It costs around 2000 dollars. It is 
possible to read only the protein-coding part of the human genome, the so-called 
"exosis", which is of interest to clinicians (a doctor working in a clinic engaged not only 
in medical practice, but also with scientific observations and research). This process 
takes less than one day and costs 500-600 dollars. Such technology of exom reading is 
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now more often used in clinical practice in Russia. (Afanasev n.d.)  
Over the past years, methods of genetic analysis, approaches to medical genetics and 
genomics have become much more understandable and accessible to the mass 
consumer. Medical clinics and start-ups offer services based on genetic analysis, in 
Russia this market is also growing and developing. Not only are end users interested in 
genetic technologies, but also corporations and states. (Krauzova 2016.) 
According to a publication on web site Rusbase “Genetic tests in Russia: players, 
problems and trends” opinions about the market of the player-based commercial sector 
became available. Rusbase is an independent on-line publication on technology and 
business, event organizer and service provider for entrepreneurs, investors and 
corporations. 
Sergey Musienko - Director General of Biomedical Holding "Atlas" said in an interview 
that a complex genetic study carried out in 2016 in Russia including about 20 thousand 
people, which indicates the early stage of the emergence of the market (Rusbase).  
The segment of the market for the diagnosis of rare hereditary diseases is about 200 
million rubles a year. Segment of tests for predisposition to multifactorial diseases - 
personal genetics - about 100 million rubles. Growth rate is about 20-30% per year. This 
information was announced in 2016 by Valery Ilyinsky, CEO of the Genotek. (Rusbase) 
Vladimir Volobuev - Managing Director and co-founder of MyGenetics noted that 
MyGenetics works in the segment of direct-to-consumer DNA tests (when a person 
receives and uses the results of DNA research independently, without recourse to 
outside specialists). According to estimates, the volume of this segment currently in 
Russia is 300-400 million rubles, the annual growth of the market is 20-25%. (Rusbase) 
2.6 PEST matrix and theoretical statements 
Table 3 summarizes the results of the PEST analysis of the theoretical information on 
the basis of the theoretical knowledge obtained from the literature and published 
articles. And Table 4 contains more detailed description of some conclusions or opening 
questions, related to research questions that will be analyzed during the empirical part. 
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POLITICAL 
- import substitution policy; 
- long registration at the state level; 
- weak development of domestic new 
products 
ECONOMIC 
- economic crisis; 
- features of financing; 
- not including gene therapy in the 
medical program; 
- high cost of tests; 
SOCIAL 
- not informing the population about new 
opportunities; 
- unavailability of the system to protect 
information about genome research. 
TECHOLOGICAL 
- rapid technological development; 
- fast obsolescence of old technologies; 
- inexpediency of using old technologies; 
- requirement of special personnel of 
bioinformatics; 
Table 3. PEST matrix of factors of influence on the development of genomic direction 
№ PEST 
group 
Statement How and why it is planned 
to open a topic in the 
empirical part 
1 Technology International market development  
The market for personalized medicine 
is very promising at the international 
level and as a consequence there is 
growing interest in genomic research, 
especially taking into account the 
cheapening of technology of new 
generation sequencing methods. 
International market plan to increase 
an average of 10.3% to 2021 year 
(Grand View Research 2016.) 
 
To understand the 
development of the market, 
it is necessary to 
understand the development 
of the industry itself. It is 
proposed to confirm this 
theory with the help of 
experts. 
2 Economic Common Russian market situation 
Russia lags behind both in its own 
development, and in principle in the 
application of methods of analysis of 
Now a good phase to start 
business in Russia in this 
area, the niche is not yet 
very busy and has all the 
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the genome. Now, at the state level, 
there are all prerequisites for the 
development of this direction and 
obtaining funding for its own 
development. 
prospects for financing. It is 
proposed to confirm this 
theory with the help of 
experts and secondary 
information. 
3 Economic, 
Social 
 
Market volume and the trend of 
changes  
According to the studies and forecasts, 
the following data were determined:  
Sequencers’ potential on Russian 
market is no more than 1000 
sequencers. The number of capillary 
sequencers is 85% of the total volume 
and is 200 000 - 300 000 analyzes per 
year (information of 2015). 
(Arustamova 2015, p.31.)  
There was information that all together 
120 analyzers have been installed, of 
which only 20 are used regularly 
(Yashina, Malacho & Sorokoletov 
2016, pp.182-186.).  
For 2015 the market of full genomic 
sequencing in Russia increases 
annually an average of 15% (Yashina 
& Malacho 2015, pp.49-55.).  
According to 2016 in the opinion of 
different experts, the increase in 
research in commercial laboratories 
and annual growth of the market is 20-
30% (Rusbase). 
On the base of secondary 
information and experts’ 
interview an attempt will be 
made the volume forecast of 
the market on the basis of 
the trend indicated in the 
theory.  
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4 Political, 
Economic, 
Social 
Problem factors for development 
The problem of registration and staff is 
one of the keys in the transfer of gene 
research from the research field to the 
medical. 
 
On the basis of the theory, it 
was revealed that in addition 
to funding, the greatest 
impact on the development 
of the field of genetically 
modified medicine is 
influenced by the problem 
with high skills personnel 
and at the macro level - 
registration bottlenecks, 
which do not allow the 
transfer of the genome 
research into the medical 
field. 
5 Economic, 
Social 
Features of financing 
The development of the popularity of 
genetic tests will strongly influence the 
inclusion of them in the mandatory or 
voluntary insurance program. If this 
does not happen, then the 
development of the market will depend 
on the willingness of ordinary people to 
pay for these services from their 
budget. 
Also an important aspect is the 
territorial distribution of medical 
institutions, as by sources of financial 
resources, the richer regions have 
more prospects for the development of 
innovative directions. 
Based on the empirical 
analysis, will be tried to 
predict the inclusion of these 
genetic services in the 
budgetary sphere on the 
basis of expert predictions. 
Also, it will be tried to find 
out whether the territory 
really influences the 
development of genetics. 
And also based on the 
survey of ordinary people, 
will be tried to build a 
forecast of people's 
willingness to pay for 
services independently, and 
try to find patterns. 
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5  Not reflected in theory - the company's 
ability to distribute a new product 
through an existing distribution set.  
This issue is not subject to theoretical 
justification, but is necessary for 
research only from an empirical point 
of view. 
The Case company expects 
to interview representatives 
of its distributors in order to 
get an understanding of the 
possibility of using current 
customers for selling and 
promoting a new product. 
Table 4. Theoretical statements 
3 APPLYING QUALITATIVE METHODS IN ANALYZING PROSPECTS 
OF GENOME RESEARCH MARKET  
This chapter presents the research approach and the methodology chosen for the 
study. The chapter continues by explaining the research phase and the methods used 
for collecting information and analyzing empirical data. 
3.1 Comparison and choice of research methodology 
Forecasting of demand of Genome Research on Russian market will have a 
quantitative estimate in quantity of tests, which can be made in this field and a 
quantitative evaluation of the sequencers that can be installed on the market. But in 
this study, it is more important not to exact the number, but trends, factors that will 
affect these indicators.  
Qualitative research is aimed at obtaining profound, detailed information about the 
subject of research. Unlike quantitative methods, they focus not on statistical 
measurements, but rely on understanding, explanation and interpretation of empirical 
data and are the source of the formation of hypotheses and productive ideas. 
(Stanway 2016.) 
Forecasting the number of Genome Research tests will have a rough estimate and 
without expert explanatory influences it will say anything to company - how this 
industry will develop, or is it possible for commercial company to take part in this 
business. 
In a quantitative study, scientists tend to objectively move away from the topic. That is 
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why quantitative research is objective in approach in the sense that it seeks only 
precise measurements and analysis of target concepts for answering the question. For 
this thesis more interesting are deeper studies of the subject, factors, behavior of this 
direction and the reasons that underlie this behavior. (DeVault 2017.) 
Qualitative research will allow capturing stereotypes that have not yet taken shape in 
the mass consciousness, to receive information at the time of its inception in the minds 
of individual consumers, which can later become mass (Crossman 2017). Qualitative 
and quantitative researches may use information about the same topic; qualitative 
methods rely on information that is not easily measurable while quantitative methods 
deal with data.  
The collection of data for the research will contain two phases:  
 Secondary data 
 Primary data  
3.2 Secondary data collection 
 The secondary data used in carrying out a so-called cabinet marketing research is 
understood as data collected earlier from internal and external sources for purposes 
other than marketing research purposes. In other words, secondary data are not the 
result of special marketing research. Such collection of information is the most 
affordable and cheapest method of conducting market research. For small and 
sometimes medium-sized organizations it is a mentally dominant method of obtaining 
marketing information. Internal sources include company reports, interviews with sales 
staff and other managers and employees, marketing information system, accounting 
and financial reports, etc. External sources are information from international 
organizations; laws, decrees; regulations of state bodies; speeches of state, political 
and public figures; data of official statistics, periodicals, the results of scientific 
researchers, etc. The existing information can be analyzed to generate new hypothesis 
or answer research questions. (Tripathy 2013, pp.1478–1479.) The collection of 
secondary information usually precedes the collection of primary information. 
In the Table 5 is presented the structure of collection secondary information. 
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 Type of 
sources 
Name of sources Comments 
Internal 
sources 
Companies’ IT “Tender” 
system  
Case company conducts 
analytical work on the control of 
publication of tenders in the 
health system and monitoring of 
the results of trades with notes 
in IT system for future analyzing. 
Internal 
sources 
Expert Reports of exhibition 
visits 
The company cooperates with 
experts who visit local and 
international exhibitions and 
congresses and provide reviews 
of reports on the latest market 
trends including Genomic 
Medicine. 
Internal 
sources 
Analytics of the operation of 
equipment, quantity and type 
of research, costs in a 
cooperating laboratory in the 
direction of genome research 
The company has a 
collaborating private laboratory, 
that is engaged in this direction 
of medicine and in which pre-
treatment data can be obtained. 
External 
sources 
http://www.zakupki.gov.ru The site on which all state 
tenders are carried out in the 
Russian Federation and 
information is available about 
the equipment supplied on the 
market of genomic medicine. 
(Zakupki) 
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External 
sources 
https:// tenderplan.ru/ The paid platform for viewing 
and analyzing data about state 
trading in Russian Federation. 
(Tenderplan) 
External 
sources 
http://base.garant.ru/  
 
Law regulation of Russian 
Federation, including Health 
care and Genomic Medicine. 
(Basegarant) 
External 
sources  
roszdravnadzor.ru Web site of The Federal Service 
for Supervision in the Sphere of 
Social Development and Health 
(RosZdravNadzor). The site 
provides information about all 
registered medical products, as 
well as violations of the 
conditions for the circulation of 
medical products in the Russian 
market. 
Table 5. (Structure of collecting) secondary data sources 
Secondary data help the researcher to get more acquainted with the situation in the 
industry of Genome Research, the trends in the changes in sales and profit, 
competitors, the latest achievements in science and technology, and other. Secondary 
information will help proceed to the correct collection and investigation of information of 
primary data.  
To determine the trends of the Russian market, it is good to consider the market from 
two sides: 
 Commercial companies  
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 State institutions 
These companies have different approaches to procurement and freedom in action. 
Unfortunately, the information of commercial companies is closed. Therefore, the main 
research will be carried out on the basis of state institutions - since information on their 
procurement can be accessed through the tenders. 
Main theoretical statements which will need to be determined by analyzing secondary 
information are common Russian market situation, market volume and the trend 
of changes and features of financing.  
Analogously to the mentioned study of Yashina et al. in 2015 and in 2016, an analysis 
was carried out of tenders of state purchases on the system tenderplan.ru, zakupki.gov 
and other related tender and registration (RosZdravNadzor) systems for last 4.5 years. 
The goal is to identify the supply of basic models of sequencers, consumables, type of 
purpose: science or clinical practice, and related services; and also identify the main 
players and brands on the market.  
To check the information about delivered analyzers at this stage, the following analysis 
procedure was made: to check state trading on the sequencers and to reveal the 
confirmation of the theory about the number of installed analyzers, and main 
consumables.  
Also in the theoretical information were data about the non-using of most of the 
installed equipment for different reasons. The reasons, why they could not be used, 
was planned to find out at the next stage of the study - during the primary data 
collection. In the analysis of secondary data, the author will try to find only confirmation 
or refutation of this theory.  
The methodology will be the following – to check where the sequencers have been 
sold for the entire time; after to check if these buyers made publications on the 
reagents, raw materials and service in the period after they bought analyzer. As usual, 
all equipment, services and materials in Russia should be purchased by state 
institution through the central state trade system (tender or auction). If after buying the 
sequencers the institution did not buy any devices for them or services, then it is most 
likely that they are not used them. 
Moreover, for this research the interest was in the purpose analyzers are used: 
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 clinical practice 
 research activity 
It will be able to find out this in the following way: 
 To check all registered analyzers, related reagents and materials in the 
Roszdarnadzor; 
 To select from the all tenders registered models and where the institution has a 
license for medical activities. 
Based on the results of the study of secondary information in this research, it will be 
possible to compare them with the theoretical definitions of the market from the 
previous chapter and make a general conclusion about the coincidence or 
inconsistency with the indicated information by experts. 
3.3 Primary data collection 
Primary data is the initial information received for exact purpose. The main 
advantages of primary information: data are collected in strict accordance with the 
precise objectives of the research task; the methodology for data collection is strictly 
controlled. The process of collecting information will involve the generation of large 
amounts of data and can use different collection method (e.g., focus group, one-to-one 
interview and other). In addition there are also different ways of making a record of 
what is said and done during an interview or focus group, such as taking handwritten 
notes or audio, video-recording. (Sutton & Austin 2015. pp.226–231.) 
The feature of data collection in this study will be the separation of target respondents. 
Based on information will be prepared interviewees of practical persons to get their 
opinions from expert side. Interviewing as research method is useful for collecting data 
that reveal the values, perspectives, experiences and world views of the population 
under study, and is often paired with other research method (Crossman 2017). It is 
planned to make an overview of existing technologies with the display value of genome 
tests based on local market conditions and international situation. In this research 
there will be made three types of questionnaire for different groups. In Table 6 there is 
information on the segmentation of respondents groups for obtaining information and 
the main tasks for this research. 
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Respondents 
group 
Group members The main purpose 
of communication 
with them 
Planned way of 
collecting 
information 
Experts  Medical or scientific 
personnel - final 
users, who 
understand what 
would make their 
working life better, 
trends in genomic 
medicine and its 
practical application. 
The goal is to get an 
expert assessment 
of the market and the 
factors that influence 
the development 
trends; to determine 
the current situation 
and the number of 
tests and growth 
(fall) trend. 
Semi-
standardized 
interview in 
personal 
conversation or 
by phone. 
Sales staff  Representatives of 
the companies who 
are now distributors of 
Case company in 
Russian regions and 
are engaged in sales 
of laboratory products 
in medical institutes. 
To identify the trends 
of genetic medicine 
in separate regions 
and the readiness of 
the present 
distribution network 
to promote a new 
product in Genetic 
area. 
Semi-
standardized 
interview in 
personal 
conversation or 
by phone. 
General 
public 
People of different 
social groups 
To identify what 
general public know 
and their readiness 
for genetic research 
Electronic survey 
Table 6. Segmentation of respondent groups for information collection 
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3.3.1 Experts’ interview 
To get an overview of the situation on the market, discussions are planned with 
specialists who are involved in the process of laboratory diagnosis and in particular of 
genetic studies. Interviewing was planned to make in semi-structured type for rod 
topics for discussion, allowing respondent to develop ideas and interviewer uses 
prompt to probe and keep up the conversation covering the broad areas. Interviewer 
may contribute but mainly one-way information flow. (Harrell & Bradley 2009.) 
The specific preparation of the interview involves making decisions on a number of key 
research questions. Such questions include:  
 the choice of respondents,  
 drafting a questionnaire,  
 determining the time and place of the interview,  
 determining the recording method. (Belanovsky 2001, p. 49.) 
a. Choice of respondents 
The number of respondents in the study is usually determined by its goals, as well as 
the financial and time capabilities of the researcher. The presence of financial 
constraints often causes the researcher to reduce the number of interviews to a 
minimum, which should increase the accuracy of their "sight." In the case of genomic 
medicine research, restrictions are also due to the fact that this area is closed and 
experts generally do not want to contact.  
In case that the totality of the surveyed respondents is considered to be homogeneous, 
the most appropriate number of respondents is about 20 people. This figure is 
determined from the practical experience of various researchers. As an example, the 
French sociologist Alain de Vulpion, specializing in the method of in-depth interviews, 
reported at a seminar in the Russian Academy of Sciences in the early 1990s that 
during the surveys he initially interviewed 50 people, but then he became convinced 
that 20 people was enough. (Belanovsky 2001, p. 50.) 
The mentioned number of respondents is sufficient to form a typological picture based 
on their answers, although it is inaccurate from the quantitative point of view, which, 
 
 
42 
 
depending on the purposes of the research, can become either its final result or a 
starting point for further work. 
The author of this research will seek to interview 20 experts who must meet the 
following requirements:  
 Have medical or biological education; 
 Have practical experience in the laboratory or genetic researches area 
(including PCR). 
When selecting respondents, the author should also ensure that the composition 
corresponds to the following at the place of work; purpose of genetic research (clinical 
practice or research activity), and work in commercial activities or in a state institution. 
It is important that representatives of all groups are included in the selected experts for 
the interview. 
As it was described in the factors affecting the economy in Russia, it is a very 
important region of respondents. Initially, Moscow and St. Petersburg are more 
developed and "rich" regions in comparison with other cities. Therefore, it is important 
that in the selected respondents were representatives of at least three groups: 
 Moscow, St. Petersburg; 
 Big cities, population more than 100 000; 
 Small towns of regional subordination. 
It is also important that the activities of commercial companies and laboratories are 
very different from government institutions, primarily because of sources of funding 
and freedom in the choice of direction of activities. Thus, it is necessary to reflect the 
opinion of both groups.  
b. Drafting a questionnaire 
Questionnaire was developed with taking into account the main research question and 
sub questions which were noted for this research. The main aim was to understand an 
expert assessment of the current market and the factors that influence the 
development trends and how they will influence the demand of genome research tests. 
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Interview was a semi-structured type and suggested that some topics could be more 
widely covered in terms of experience and expert’s opinions.  
Drawing of basic topics and questions are indicated in the Table 7 with some 
comments from researcher. But in fact, in a semi-structured interview, questions can 
be exchanged in places or even missed. In the mentioned form are the basic questions 
that the interviewer needs keep in mind. 
Reg. 
№ 
Name of respondents: 
Specialization: 
Education: 
Region (city): 
Place of work: 
Area: clinical practice / research 
activity 
Date of interview:  
Place: 
Interviewer: 
№ Topic/question 
1 What is your experience in genome research tests? 
2 How do you evaluate developments on the world market?  
What are the basic manufactures you would advise?  
3 What do you think about Russian developments? 
4 What do you think is the future of this direction? 
5 Is it necessary to use the genome research in medicine?  
What tests would be popular in your opinion? 
6 Is it necessary to include the genome sequencing of the genome in a mandatory diagnostic 
program? 
7 How can we determine the volume of the equipment market and the market for research? 
8 Do you think people are ready to pay for this service themselves? 
Table 7. Questionnaire (structure form) of experts’ group 
c. Determining the time and place of the interview  
Representatives of the group are quite scattered and each had to choose the right 
approach and way for the interview. 
The Case Company cooperates with several experts in the framework of its actions – 
these experts were interviewed in a personal conversation in the office of the company 
or at the direct place of their work (in the lab or place of production) in the period from 
01 August to 31 August 2017. 
Another part of the experts was interviewed in October on the exhibition “Laboratory 
City – 2017”. Eleventh-thirteenth October 2017 The Federation of Laboratory Medicine 
held the III Russian Congress of Laboratory Medicine, which brought together 
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laboratory specialists from all regions of Russia on its site. Within the framework of this 
congress, there are many specialized lectures, including some on the direction of 
genomic technologies and molecular diagnostics. In addition to an extensive program 
of scientific and practical events, there was exhibition "Laboratory City", where major 
players of laboratory market had their own booths and presented laboratory 
equipment, reagents, consumables and some new technologies.  
Case Company also had a booth in this exhibition and the researcher used the chance 
to communicate with experts to identify the issues of this survey. 
After summing up the results, the researcher checked whether all the requirements for 
the choice of the respondents were satisfied and whether the number of interviews 
was sufficient. The missing 5 interviews were conducted by phone - they were 
representatives of small towns in the regions.   
d. Determining the recording method 
Methods for recording interviews for documentation and subsequent analysis include 
audio typing, video recording, handwriting and memorization. Today, a dictaphone is 
usually used for this. In this case, the interviewer can focus on the topic of the 
interview and the dynamics of interaction. The words, the tone to which they are 
pronounced, pauses and the like are imprinted forever, and then you can return to 
them again and again. (Polgar & Thomas 2011, p.110.) 
The author originally planned to record at least a few interviews to provide the 
management with the audition and justification why some conclusions were made in 
this way. But during first interviews it was revealed either that the respondents refused 
to admit that this sphere has not been thoroughly studied yet and they would not want 
their words "to go somewhere" and ruin their reputation. Or they were constrained and 
could not say something freely until the recorder was turned off.  
On the basis of the above, it was decided to use the method of written records with the 
author's notes.  
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3.3.2 Sales staff interview 
One of sub-questions of this research was to understand the ability for Case Company 
to promote new products in Genetic area through an existing network of distributors 
and also to identify the trends of genetic medicine in separate regions. 
Case Company worked directly with final users (state hospitals of private clinics and 
laboratories) in Saint-Petersburg, where the head office is situated, and in Moscow, 
where a branch of the company is situated. In all other regions company works through 
a distributor net and through local companies. For this step of research Case Company 
decided to make survey of these clients to understand what they know about the area 
of gene medicine and their opinions about the future of this direction. 
The information was also received in the form of a semi-structured interview with the 
possibility of expanding the answers.  
a. Choice of respondents 
Formulation of respondent list was prepared and confirmed two times.  
 “First list”. One main distributor in each region was selected, where company 
has active promotion. In total there were around 30 companies, which now re-
sale Case company’s products and have strong positions in regions in this field. 
26 agreed to cross the interview, others cancelled.  
 “Second list”. A new selection of companies was made – clients of Case 
Company, who are involved in genetic medicine more. 
b. Questionnaire for sales staff 
The questionnaire for sales personnel differed from the questionnaire for experts and 
was developed specifically taking into account factors related to sales process and 
presented in the Table 8 with some comments from researcher. 
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Reg. 
№ 
Name of respondents: 
Specialization: 
Education: 
Region (city): 
Place of work: 
Area: clinical practice / 
research activity 
Date of interview:  
Place: 
Interviewer: 
№ Question 
1 What is the main direction of your company’s activity (main products)? 
2 Do you have any experience in supplying molecular diagnostics? 
3 Do you cooperate with the research institutions? 
4 Are you familiar with the topic of genome sequencing and related equipment? 
5 If the company promotes this equipment, have you got opportunity to implement it in your 
region? 
6 Do you think there is a prospect for this direction if the cost of the test is USD 3000 and it is 
not included in the budget programs? 
7 Is there any regional support for the direction of genetic tests? 
Table 8. Questionnaire (structure form) of sales staff respondents 
c. Determination of the time and place of the interview 
The interview of “First list” was conducted between 01 August to 20 August 2017 with 
the assistance of an internal call center specialist. The interviews were made by phone 
or skype.  
After the preliminary conclusion of results a decision was made to make a second 
selection of respondents. Additional representatives of companies from the “Second 
list” were interviewed from 09 October to 16 October 2017, also by phone personally 
by researcher. 
d. Determining the recording method 
Unfortunately, the Case Company recently experienced an unpleasant experience with 
recording calls, so recording calls is not working now. In the beginning of 2017 when a 
special internal call-center specialist was taken to the staff, the technology of recording 
calls with the interlocutor's notification of the recording was experimentally introduced. 
Afterwards it was possible to listen and analyze not only calls by the mentioned 
specialist, but also by all employees, including sales managers. 
But the company's customers began to complain massively and began to call to 
manager’s mobile phones or use correspondence like mail or messengers. In the 
company's conversations with third parties there is no any secret or illegal information, 
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but customers complained that they felt they were under surveillance. 
It was decided to cancel this tactic, so for the phone interview audio recording was not 
available. Therefore, despite the advantages of audio recording of the interviews, the 
researcher used the method of manual recordings during conversation. 
3.3.3 General public survey 
The purpose of talking with people was to identify what ordinary people know about the 
area of genetic medicine and their readiness for such tests. And on the basis of their 
opinion to forecast how this area can evolve in the future in terms of final consumers. 
The market of medicine is certainly specific - products on the market are not always 
chosen by users - as a rule they are "imposed" by their medical institutions or certain 
standards. But in any case, the trends of personalized medicine go forward and the 
imposition of ordinary patients will also be important. 
a. Choice of respondents 
For the selection of ordinary people for the survey, some of the same rules applied as 
for the survey of experts, like geographical position. But also new requirements were 
added:  
 In the survey had to participate people of different social groups; 
 People should have no medical or biological backgrounds. 
For the survey, it was decided to obtain data from at least 40 people. But after the 
completion of the survey of 26 people it was found out that there were not enough 
people from the regions (Most from Saint-Petersburg, because researcher distributed 
information about the survey through their friends) and the invitation about the survey 
was sent to the regions and 16 more answers were collected. As a result, the survey 
involved 42 respondents. 
b. Questionnaire 
The survey was conducted in electronic form without contacting the participant directly. 
It was made in Russian language and contained not only the users' forecasts about 
gene medicine, but also some personal questions for determining their social group, 
preferences and habits. Questionnaire consists of following topics and questions, 
 
 
48 
 
presented in Table 9. 
№ Question Answer options 
1 Age Number 
2 Place of residence (city) Selection 
3 Position/specialization Selection 
4 Average monthly income level High 
Middle 
Low 
5 Are you familiar with the concept of sequencing of the 
genome? 
Yes/No 
6 Are you ready to pay $ 3,000 to fully decrypt your genome and 
know about all the predispositions? 
Yes/No 
7 If not, how much do you think should such a test cost in USD? Number 
8 If there is a possibility of not full research but only parts of the 
genome associated with a certain area (eg predisposition to 
breast cancer, or mutation gene), it would be interesting 
Yes/ No /Depend from price 
 
9 Which areas are most interesting? Oncology/ 
chronic diseases (heart, blood 
vessels and others)/ 
 Mutations/Related genetic 
features/ Other 
10 Would you prefer to do such a test in a private clinic or state? Private/State 
Table 9. Questionnaire (structure form) of survey of general public respondents. 
c. Time and place  
When conducting an electronic survey, the time and place of the interview is not so 
important, since respondents have the opportunity to reply at any convenient time, 
regardless of their location. On-line survey with using Google tools was conducted from 
2 to 24 October 2017. In Figure 5 is shown the title page of the Survey.  
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Figure 5. Main page of on-line survey 
d. Recording method 
Google tools can give the data in a convenient electronic format. Data was uploaded 
for analysis to Excel for later analysis. The results of the report are listed in the 
appendix 3.  
3.4 Methods of analysis 
Since the research was make in two main stages: analysis of secondary data and 
analysis of primary data, several approaches to analysis were used. 
3.4.1 Secondary data analysis 
During research of secondary data from internal and external sources were used two 
general approaches for analyzing existing data: 
 the ‘research question-driven’ approach; 
 the ‘data-driven’ approach.  
In the research-driven question approach, there is a priori hypothesis and then 
researcher looks for suitable datasets to find answers on the question. In the data-
driven approach the researcher glances through variables in the available information 
 
 
50 
 
sources and decides what kind of questions can be answered by the available data. In 
reality, the two approaches are often used jointly and iteratively. (Cheng & Phillis 2014, 
pp. 371–375.) 
In the analysis the researcher start with a general idea about the question or hypothesis 
and then looks for available datasets which contain the variables needed to address the 
research questions of interest. Main theoretical questions which will require secondary 
information are:  
 Common Russian market situation,  
 Market volume and the trend of changes, 
 Features of financing. 
3.4.2 Qualitative Content analysis 
For analyzing data from Expert and Sales companies’ respondent groups for primary 
information analyzes it will be possible to find regularity and common opinion. 
Qualitative Content Analysis method was used which defines itself within this framework 
as an approach of empirical, methodological controlled analysis of texts within their 
context of communication, following content analytical rules and step by step models 
(Mayring 2010, pp. 43-55).  
Presentation of findings will be presented in tables and matrices. This way is useful 
particularly when quotations are used to articulate the findings by interview. Refinement 
of the analysis may well occur even as the manuscript is still being written in final form 
(DeVault 2016). 
In the procedure of content analysis was made the selection of semantic units that are 
directly relevant to the problem under research question. In the theoretical part was 
fixed a number of theories that related to the research questions and questions which 
should be opened more detailed in the empirical part. These theories relate to the 
following topics: 
 International market development 
 Common Russian market situation 
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 Market volume and the trend of changes  
 Problem factors for development 
 Features of financing 
 Current distribution set of Case company  
Since the interviews were conducted in semi-structured form, much of the information 
received from experts and sales representatives was logged not in the form of an 
organized completed questionnaire, but in the form of a written text, to the author's 
digressions and sometimes respondents leaving the topic or on the contrary of deeper 
development of one topic, while not having concepts about something. 
The next stage was one of the most important in the whole process of content analysis. 
This is the codification of text units. Its essence is to develop rules for correlating 
semantic units with a list of categories of analysis. The result of the codification phase is 
the development of a codifier, which includes not only a list of observed indicators, but 
also data on the document in which they are present (Flick 2009, p. 334). 
After forming a sample of messages, selecting semantic units and creating a codifier, 
researcher went directly to the very analysis of the texts of interviews. In practice, this is 
expressed in the compilation of a code table in which each observation (the semantic 
unit) refers to a particular type or class in accordance with the rules of the codifier. In 
Table 10 are presented the basic codes that were developed and used by the author for 
comparing information and searching for the answers to the questions asked is 
discussed. 
Basic Codes Theoretical statement/ open 
research question 
USA, Illumina, Roche, Thermo fisher, Oxford 
Nanopore, Bio-rad, China, Beijing  
International market 
development 
Skolkovo, Nanofor, market frozen, Russian research 
center (RRC), test cost, high test cost, non-use. 
Common Russian market 
situation 
Market of equipment, market of tests, market growth, Market volume and the trend of 
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import substitution, tender, Medicine usage changes  
Registration, staff, bioinformatics, budget support. Problem factors for 
development 
Medical program, insurance, mandatory diagnostics, 
budget 
Features of financing – state 
politic 
Solvency, ability to pay, insolvency, inability to pay, 
test cost 
Features of financing – 
individual readiness for pay  
Table 10. Codifier table 
3.4.3 Statistical Survey Analysis 
For the analysis of surveys of ordinary people, the Content Analysis with special coding 
is not required – interview form in electronic form is a closed one, aimed at obtaining 
statistical data and searching for patterns. This Statistical Analysis needs to  find 
answer on one of research sub-questions – “Knowledge, expectations and readiness of 
ordinary people for the topic of genome research”. For this study, it is interesting to 
understand if the state policy of financing in the field of genetic medicine is not being 
implemented in the next few years, and whether the society is ready to incur expenses 
on its own. 
Statistical Analysis was made on the basis of survey and used the most straightforward 
form of analysis, and one that often supplies much of the basic information need. It was 
planned to tabulate results, question by question, and it was done using an original 
questionnaire and writing on it the frequency or number of people who ‘point each box’.  
Relative values in statistics are generalizing indicators that reveal the numerical form of 
the ratio of two matched statistical variables. In the calculation of relative values, two 
absolute ones are most often compared, but one can compare both the mean and 
relative values, obtaining new relative indices. The simplest example of calculating the 
relative value is the answer to the question: How many times is one number greater 
than the other. (Callegaro, Vehovar & Manfeda 2015, pp. 187-191.) 
Qualitative data from survey needs to be evaluated as available information and data 
are increasing permanently in modern times. There are some difficult methodic 
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approaches  for consistently transforming qualitative contents into a quantitative form 
and enabling the appliance of formal statistical methodology to get interpretations and 
insights which can be used for sound decisions and which are bridging qualitative and 
quantitative concepts combined with analysis capability. (Loehnert 2010.) 
But this survey research does not require such detailed elaboration of mathematical 
concepts and statistic correlations and will be reduced to an estimation of relative 
indicators - like "how many people are ready to pay for carrying out gene research, how 
much they are ready to pay" and a small search for regularities - for example, regional 
affiliation or age. Qualitative answers, if possible, will be transferred to a quantitative 
assessment, or if conditions are encountered, codes or interesting information will be 
reflected in the conclusions as an addition. 
4 EMPIRICAL ANALYSIS OF THE GENOME RESEARCH MARKET 
4.1 Analysis of the market and trends through tenders and registration system 
Analogously to the mentioned research of Yashina et al. in 2016, an analysis was 
carried out of tenders of state purchases on the system tenderplan.ru and related 
systems mainly for last years since 01.01.2012 till 31.08.2017. The goal was to identify 
the supply of basic models of sequencers, consumables and related services. And also 
to identify the main players and brands on the market. 
In addition, there was a number of narrower tasks, connected with theoretical 
background and related to common Russian market situation, market volume and the 
trend of changes and features of financing. 
Determining the main characteristics of the market 
In the period from 01.01.2012 to 31.08.2017 were found 226 tenders for sequencers, 
raw material for them, or service for the total 911.2 million rubles of contracts. Of these, 
31 tenders were for the supply of the sequencer and the amount of contracts was 669.8 
million rubles. The Graph 1 shows the percentage distribution of the objectives of the 
tenders by quantity and Graph 2 by sum of contracts.  
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Graph 1. Share of quantity of state tenders in the field of sequencing by object of 
procurement from 01.01.2012 to 31.08.2017 
 
Graph 2. Share of sum of contracts of state tenders in the field of sequencing by object 
of procurement from 01.01.2012 to 31.08.2017 
Data on the results of tenders do not give us a clear view about theoretical statements 
of market volume on current day, because:  
Firstly, only state trades were checked, and there was no possibility to check current 
situation on commercial market.  
31 tenders;  
14% 
39 tenders;  
17% 
159 tenders;  
69% 
sequencers and
equipment
reagents and
materials
support and repair
355 mln rub.; 
39% 
289 mln rub.; 
32% 
267 mln rub.;  
29% 
sequencers and
equipment
reagents and
materials
support and repair
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Secondly, in the process of analyzing tenders, it was revealed that state institutions 
purchase materials or repairs, but there were no noticed tenders for the sequencer 
itself. This could mean that sequencer was placed there without a tender. 
In the Appendix 1 the Case Company can find a list of distributors that currently operate 
in the market for the supply of sequencers and materials to them and most often (more 
than 6 participation in tenders) participate in public procurement. This information gives 
us an understanding of the competition in the genomic research market.  
According to the theory on the Russian market in 2015, more than 85% are occupied by 
sequencers of the capillary type (the old generation). In fact, in the analysis of trades, 
the models that mainly participated mostly belonged to a new generation sequencers. In 
principle, this can neither subjoin the theory nor disprove it, because if the institutions 
were supplied with old type analyzers and they are not used, then it will not see trades 
for materials to them either. 
Geographical location   
The distribution by region was carried out by analyzing the location of the buyer's 
actions in the tenders trading by sequencers and noted in Graph 3.  
 
Graph 3. Distribution of state trading on a regional basis 
This analysis underpins theoretical statements that there is larger financing of medicine 
in the regions that are tax donors. 
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Trend  
According to theoretical estimates by experts, in 2015 and 2016 the forecasts were as 
follows: 15% market growth as a whole, 20-30 % market growth annually in the 
commercial sphere. 
During analyzing tenders, it was revealed that the growth trend had greatly increased in 
the last two years and if in 2015 there were only 23 tenders on this subject, then in 2016 
there were 55, which is a growth of more than 100%. The dynamics of the competitions 
held in the direction of the sequencers is indicated in the graph 4. 
 
Graph 4. Development of the area of genetic research on the basis of the number of 
published trades in years 2012-2017. 
Determination of usage type  
In theory, it was pointed out that most of the sequencers are used for research 
purposes and are not yet advancing to the medical field. According to web site 
RosZdravNadzor in Russian Federation now only 7 models of sequencers have 
registration certificate, 2 of which have already expired registration date. Models are 
mentioned in Table 11. 
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Number of 
registration 
Date of 
issue 
Expire 
date 
Name of model Company, who 
made registration, 
Country 
Manufacture, 
Country 
МЗ РФ № 
2001/444 
08.05.2001 08.05.2011 DNA Analyzer 
Automatic 
(Sequencer) 
Model 
"ALFexpress II" 
Amersham 
Pharmacia Biotech 
Export GmbH, 
Germany 
Amersham 
Pharmacia 
Biotech AB, 
Germany 
МЗ РФ № 
2002/646 
14.08.2002 14.08.2012 DNA Analyzer 
Automatic 
(Sequencer) 
ALFexpress II 
Amersham 
Biosciences AB 
Sweden 
Amersham 
Biosciences AB 
Sweden 
РЗН 
2014/1568 
29.04.2014 Indefinitely Genetic 
sequencer MiSeq 
in the following 
versions: MiSeq, 
MiSeqDx 
ООО 
"ИнтерЛабСервис" 
Russia 
Illumina, Inc, 
USA 
ФСЗ 
2012/12198 
30.07.2012 Indefinitely Sequencer 
genomic "GS 
Junior" with 
accessories 
ООО "Рош 
Диагностика Рус" 
Russia 
Roche 
Diagnostics 
GmbH, Germany 
ФСЗ 
2012/13397 
21.12.2012 Indefinitely Sets of reagents 
and supplies for 
the sequencer 
genomic GS 
Junior 
ООО "Рош 
Диагностика Рус" 
Russia 
Roche 
Diagnostics 
GmbH, Germany 
ФСЗ 
2012/13293 
29.11.2012 Indefinitely Sequencer 
genomic GS FLX 
+ with 
accessories 
ООО "Рош 
Диагностика Рус" 
Russia 
Roche 
Diagnostics 
GmbH, Germany 
ФСЗ 
2009/05210 
04.06.2010 Indefinitely The system for 
DNA sequencing 
(OpenGene DNA 
ООО "Компания 
Медсервис" 
Siemens 
Healthcare 
Diagnostics, 
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Sequencing 
System) Trugene 
with accessories 
and 
consumables 
Russia USA 
Table 11. The list or registered analyzers in RosZdravNadzor 
Thus, only 4 models can be used for clinical research and use in medicine: 
 MiSeq, MiSeqDx 
 GS Junior 
 GS FLX 
 OpenGene DNA 
Other sequencer presented on the market can be used only for scientific research. 
To determine the model of the delivered sequencers, the researcher had to go into each 
contract and check the conformity of the registered brand and model from the contract, 
and also to check the application scope of the buyer (medicine or research). Of the 31 
tenders, only 3 procurements were identified as for clinical aim, the remaining 
sequencers, even if they were delivered to medical institutions, should be used for 
research purposes and not the basis for setting the diagnosis for example.  
The level of use of sequencers 
According to the articles at the moment, about 120 sequencers by 2016 have been 
delivered, but only 20 of them are actually used (17%). The author mentioned all the 
sequencers delivered to both state and commercial companies. This study will only 
concern state trades because of the lack of opportunity to analyze commercial 
companies. With the help of the system of tenders, an investigation was carried out that 
supported this theory. 
Based on the analysis it was revealed that out of 92 state customers only 46 during this 
period made a one-time purchase, which is 50 percent. The remaining 46 made 
purchases 2 or more times. But in the opinion of the researcher, this conclusion cannot 
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serve as a refutation of the theory, since the analysis of the tenders for selected period 
does not give a complete picture of the delivered analyzers, bypassing trades for 
research and approbation ways, for example. 
4.2 Analysis of primary information 
With the using of mentioned methods of analysis, the collected primary information was 
analyzed in the form of an interview, and the following results were found.  
4.2.1 Summary and results of experts’ interview 
Interviews with experts include respondents from different areas for the most complete 
representation of the object of research and search for answers to questions. Appendix 
2 contains translated interview protocol with one of the respondents, as an example of 
filling out. 
Based on the results of the encoding of the data, including the theoretical statements, 
the following results were concluded. 
International market development  
Of the 20 respondents, most demonstrate interest and perspective in the development 
of genomic technologies and their application in medicine. There are also few scientists 
who think that DNA sequencing will not leave the walls of research laboratories. Two 
respondents suggested that these technologies are too scientific and expensive to be 
applied to mass analyses.  
Graph 5 shows the number of known world brands based on the views of the 
respondents.  
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Graph 5 Familiarization of experts with world brands 
The rest of the respondents, especially those who are involved in molecular diagnostics 
more deeply and take part in international conferences, state that there is a future for 
genetic tests. All interviewed respondents marked the same brands, known on the 
international market and were very skeptical about Russian developments in this area. 
Common Russian market situation 
The survey involved only three people who are directly related to the work of 
sequencers, the rest do not have such opportunity but most specialize in molecular 
diagnostics and are associated with this direction.  
Experts assess the overall situation on the Russian market as "lagging behind", "lull", 
"poverty". The declared Russian developments are noted by most experts as obsolete, 
and the use of capillary sequencers (Sanger method) is not predicted due to the high 
cost of genome research.  
According to the opinion of experts, the market of research is now mainly for scientific 
research and the market are waiting for the government to take steps in the transition of 
the genome research to the medical sphere.  
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Market volume and trend of changes 
The main consumer of sequencers is now the scientific research center, which uses 
genomic research for the most part for population tests and genetic predispositions to 
diseases go only at the third level, after the identification of family ties.  
Many experts (15 from 20) noted the growth of commercial influence in recent times and 
said that now these genome tests have become available in private laboratories and are 
in demand among wealthy people. But the problem is that human genetics is 
changeable and the results of such test can become outdated after a couple of years 
under the influence of external factors like the environment or internal, like food or bad 
habits. 
If genomic researches pass to the medical level due to the state program then 8 experts 
noted that this would go into the routine of compulsory diagnostics. In this case, the 
equipment will have to stand at least in the Central District Hospitals. This assumption 
allows us to calculate the volume of the market for sequencers and tests for the 
projected inclusion in the compulsory insurance program. 
Problem factors for development 
The overwhelming majority of experts spoke about the issue of registration for making 
tests on the genome for medicine aim. Respondents noted that 1-2 years of registration 
deadline can stop the development process, since this area is quite variable and the 
reagents that undergo the registration process may be already outdated. 
Also, the question that was not much raised as a problem in this thesis was noted by 
the majority of respondents - the availability of specialized staff for interpreting and 
issuing results. 
Also, the problem for the development of the field of genome research is the cost of 
research. Now full genome code interpretation costs 2000 - 3000 dollars, a narrow, 
directed to some area about 300 - 500 dollars. What makes the test so expensive? In 
Table 12 are presented the results of the experts' opinion.  
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The constituents that affect the cost of 
the test 
Level of influence 
(1 – strongest, 6 – weak) 
Costs for specialized staff 1 
Expensive technique 2 
Overpriced market prices 3 
Cost of equipment 4 
Reagents 5 
Maintenance costs 6 
Table 12. Factors affecting the cost of the test 
Also, 9 experts raised the topic of storage and legal responsibility of data. This topic 
was not considered at all in this thesis, and not learned during theoretical background. 
According to the respondents, this topic is not very well developed in the Russian 
Federation from legal side and can be a problem because it prepossesses storing or 
transmitting information about a person – full information about his predispositions, 
illnesses of features. As one of the experts said “If the database with genome 
information is stolen and distributed, would you marry a person who has a mutation in 
the genome or a propensity for alcoholism? Or if the employer wants to check the 
employees… how to be with ethical point of view”.  
Features of financing  
According to theoretical notes, the main breakthrough in the development of the market 
will be if these tests are included in the program of mandatory or at least voluntary 
insurance program. The opinions of experts were divided according to the forecasts of 
this issue and presented in Graph 6.  
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Graph 6. Expert opinion on the need to include genomic research in the insurance 
program 
Respondents, who answered “YES”, also commented on the following:  
 “When the test will cost $ 100”  
 “When there are local products and the government will have to support them” 
 “In mandatory unlikely, but in the premium voluntary will be cartainly”  
Respondents, who answered “NO”, also commented on the following:  
 “There are cheaper methods like PCR and ELISA, why need to use something 
more” 
 “This science is far from practical” 
 “It will be impossible to equip all hospitals with devices”  
 “No staff in the country, they will learn at best in 10 years”  
At the same time, experts assess the high probability of popularization of these tests 
among the population and the development of this area in terms of personal payments 
of patients. Most experts believe that people would already be ready to pay, but they 
simply do not know about this possibility.  
All respondents noted that the use of sequencers is primarily interesting in the diagnosis 
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of cancer, prenatal medicine, diagnosis of autoimmune diseases and gene mutations.  
4.2.2 Summary and results of general public survey 
The idea of researching what common people think about the genome exploring 
appeared after studying the theory and communicating with some experts that many 
people would be ready to pay for deciphering their genome and without special budget 
programs. The result of this analysis gave an answer to the research sub-question – 
“Knowledge, expectations and readiness of ordinary people for genome research”. 
In the electronic survey took part 42 anonymous people. In the study were not accepted 
people with medical or biological background, since the goal was to determine what 
people think and if they are ready for such tests or not. In Appendix 3, the translation of 
the survey report with details of the data is indicated; this chapter will reflect the main 
identified patterns. 
The author tried to reflect all the groups according to: location, age and income levels. 
The target groups are shown in Graph 8. 
 
Graph 7. The structure of the survey respondents by age, location, income  
A survey of people showed that people not related to medicine or science have not a lot 
of information about the possibilities of genome research – only 5 respondents have 
some knowledge about genome tests. At the same time, people's willingness to pay 
around of USD 3000 per one full genome research splits in half – 22 respondents are 
ready, 20 are not ready. Dependence on income, age and income is shown in Graphs 
9, 10 and 11. 
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Graph 8. The willingness of people to pay for the genome research, the age 
dependence. 
The logical conclusion is that the older people become the more likely customers as 
they are willing to spend money on their health and all sorts of tests. An interesting 
conclusion is that in the age group 18-25 the separation is 50/50, but it can be related to 
the desire for mutation studies when planning to have children.  
 
Graph 9. The willingness of people to pay for the genome research, the geographical 
location dependence 
Of course, the survey was accepted by the majority of respondents from St. Petersburg 
or Moscow. But even if one analyzes at the preferences inside the region type, it can 
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conclude that the smaller the city - the less willingness to pay. 
 
Graph 11. The willingness of people to pay for the genome research, the average 
monthly income dependence 
An interesting conclusion is that all respondents with low income would refuse to pay, 
but all respondents with high - agreed. In principle, this is logical, for a person with a 
good income $ 3,000 is not such a huge amount to refuse to know everything about 
yourself. At the same time, a greater number of respondents consider that such a test 
should cost no more than $ 500. 
When identifying an area that would be of interest, an important role is played by 
oncology. Graph 12 shows how the respondents were interested in the application. At 
the same time, 36 respondents (even those who are not ready to pay), said that they 
would prefer not a full research but a testing for some area for specific task. At the same 
time, people would prefer to do such tests not in commercial laboratories, but in state 
centers (Graph 13), which proves that Russian people generally trust the state 
programs in general. 
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Graph 11. Respondents’ interest in the field of test application 
 
Graph 12. Respondents’ preference in the place of research 
5 RESULTS AND DISCUSSION  
5.1 Prediction of genome research on Russian market 
Sequencing the genome is the right way to learn about yourself: good and bad things. 
Genetic predispositions and risks, features and potential diseases - the determination of 
the nucleotide sequence of DNA and its subsequent interpretation will tell more than all 
the analyses known before. The results of sequencing - the most detailed instruction for 
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the doctor on the treatment of a specific patient, designed to ask the world's diagnostics 
an astounding vector of development. After all, when in one medical file all diseases are 
prescribed at once - and even those that have not yet shown themselves - the doctor 
can only choose consistent goals and treat. 
The research showed that the international market has significant development in this 
direction and many Russian experts are monitoring new technologies. Over the past 5-7 
years, the technology has made great progress, and the time that it needed for make 
the test and the cost of research have been reduced from tens of thousands of dollars 
to 1,000-3,000 US dollars for full genome research. All this created favorable factors for 
the development of the market from a commercial point of view. 
The Russian market is now a little frozen. Locally developed equipment and launching it 
to the mass using is already outdated and despite the fact that somewhere else it is 
used (according to the data of tenders and experts) is soon will go to the archive due to 
no economic performance.  
News about new Russian developments remains only like news and do not have access 
to a practical market. Although within the framework of the modern policy of import 
substitution, funds can be allocated and projects can be forced to complete. But there is 
some theory of experts that it is more important for the government to launch not 
progressive developments and technologies, but simple and massive things that are 
used daily in medicine in order not to depend on foreign supplies. 
In any case, sooner or later the Russian market of gene research will move into a 
medical area and will be widely distributed. Forecasts of experts say that from 5 to 15 
years are necessary for the Russian market to put technology of genomic sequencing 
into mass use.  
5.2 Factors of influence on genome research development in Russia 
A significant development will be if these tests reduce the cost and are included in the 
program of mandatory insurance. The table 13 shows the factors and degree of their 
influence on the development of the trend on the basis of theoretical statements and the 
results of research.  
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Theoretical statement Level of influence, comments 
International market 
development 
Strong influence, the rapid development of the technology 
market on the one hand gives new opportunities to the 
market, but on the other, creates such a problem as the 
rapid obsolescence of equipment and technologies. 
Common Russian market 
Features 
Strong influence - the backlog in technology and financing 
makes Russia lag in the direction of full genome 
research, but now there is a real chance to launch these 
projects, taking into account the favorable experience in 
foreign markets.  
Market volume and the 
trend of changes  
Not a certain level of influence. The volume of the 
Russian market is in principle large, because the country 
is large with a huge population. The definition of the 
demand itself will evolve depending on which way Russia 
will go - if it enters into mandatory medical research, and 
then the market will be very large. If the trend is to let 
people themselves pay for such gene research, then the 
market growth will not be so rapid, but will proportionately 
be depended from the cost of the test - the lower the cost, 
the greater the demand.  
Problem factors for 
development 
One of the main problem factors, that most experts and 
theoretical applications indicate is registration – the 
procedure of registration of the medical device taking 
around 2 years can force to situation that when a 
company is ready to start-up the promotion and sales of 
equipment on market,  this equipment has become 
obsolete. Now the issue of registration is actively 
discussed at the state level and everyone hopes that 
soon this issue will be resolved. Eliminating this problem 
can significantly reduce this impact on the development of 
the market.  
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Also, the problem of personnel for the decoding of 
genomic studies is widely discussed - this problem greatly 
affects the cost of the test and no prerequisites have 
been found to solve this problem.  
Features of financing – 
state politic 
Strong influence. Of course the main factors are the 
features of financing and budget allocation. Here, Russia 
can go for two ways (include in insurance or not) with an 
equivalent probability. But also the cost of the test can 
significantly affect the decision of the state.  
Features of financing – 
individual readiness for 
pay  
In general, people are ready to pay for such research 
mostly in large cities and if they have high incomes. 
Therefore, the market for commercial research has real 
opportunities for growth, especially if the promotion and 
information of the population were wider.  
Table 13. The influence of theoretical statements on the development direction 
In a more general way, a PEST analysis was used to analyze the macro environment, 
the results of the research in PEST model are shown in Table 6. 
Group Level Comment 
POLITICAL   
import substitution 
policy 
Middle So far there are no special prospects for local 
development; the market is oriented towards foreign 
companies. 
long registration at 
the state level 
High While a new product is registered, it may already 
become obsolete. 
weak development of 
domestic new 
products 
 
Middle Program of the government for financing the 
development of essential goods. 
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ECONOMICAL   
economic crisis 
 
Middle Well, it happened, the value of money decreased, 
but somehow the country still lives and develops. 
high cost of tests High Too expensive test price does not allow making it 
mass. 
features of financing 
 
High The question of where to pay, from insurance, from 
the budget or personal money is very serious 
not including gene 
therapy in the 
medical program; 
High The most important for the development of the 
market in the direction of medicine. 
SOCIAL   
not informing the 
population about new 
opportunities; 
Middle It is important for the development of private sector, 
but at the macro level it can be not so important, 
because mass character will be only including it in 
the state program. 
unavailability of the 
system to protect 
information about 
genome research. 
Middle While not so much research is not an important 
issue, when the mass character begins it will be 
possible to use the achievements of the foreign 
states. 
TECHOLOGICAL 
 
  
rapid technological 
development 
 
High The market reaction for rapid technological change. 
fast obsolescence of 
old technologies 
 
High Buying expensive equipment that may soon become 
obsolete. 
inexpediency of 
using old 
technologies 
High Same. 
 
 
72 
 
requirement of 
special personnel of 
bioinformatics 
High Influence on the cost and speed of the test and on 
the possibility of its implementation. 
Table 14. Evaluation of the factors of PEST analysis 
5.3 Determination of genome research demand 
The information about the current market and the volume of tests conducted is very 
different and can use completely different bases for determining. 
Considering Market of equipment - new generation sequencers, there is information 
that the potential of the market is 1000 equities, 120 units have already been supplied, 
and only a small part of them is used. 
Using the theory of market calculation, proposed by the experts during the interview, it 
is possible to determine the following volumes. 
In the future, with a mass market expansion, sequencers must be located in each 
research institute for scientific research; plus, if this direction goes to the medical 
sphere, and will be a regular research for diagnosing diseases, then in every central 
district hospital. 
According to business map of Russia, noted in Figure 6, 1812 Research institutes 
located throughout all regions of Russia were found. Of course, most of the percentage 
is occupied by Moscow, St. Petersburg and major cities.  
 
Figure 6. Russian business map of Research institutes 
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If in each Research institute there is 1 sequencer for carrying out researches in their 
study area, the market of scientific research will be 1800 units of sequencers. 
Further, the following theory is that if the sequencing of the genome passes into the 
medical field and becomes mandatory for the diagnosis of diseases, then the sequencer 
should be at least in large central district hospitals. According to previous submissions 
of the Case Company - in Russia there are around 600 such hospitals with departments 
of diagnostics, which can accommodate such large equipment. Thus, the market only 
for state use will be around of 600 units of sequencers.  
Now in Moscow there are about 10 private laboratories that offer a full of genomic 
sequencing, and 6 laboratories in St. Petersburg. If assume that with mass development 
in medical area in each major city (region center - 85 regions) there will be at least one 
commercial organization carrying out such tests, then to the total volume will be added 
around 100 sequencers. Thus, according to this theory, the volume of the market (and 
medicine and research) will be not less than 2500 sequencers (Graph 14).  
 
Graph 13. Forecasting of Russian market structure for genome research equipment 
If we try to determine the volume of genome tests conducted, according to the 
information from the literature, so far the sequencing of the genome has been 
conducted by about 60,000 -100,000 people in Russia (for whole time of sequencing 
history in Russia). 
If genomic research is not included in the insurance program, and they will be available 
only for the personal payment of citizens, the development will not be so rapid. A study 
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of the people's experience shows that 22 out of 42 people are ready to pay for it; this is 
already a good result for the market forecast. 
If the insurance program is changed, and the research is included in politics, then 
Russia can follow the path of America, where a genomic study has already been made 
to 5 million people (which contributes 1.5 % of the whole population) during five years. 
Thus, the growth in Russia with the purchase of an insurance program can be around 
2.5 million genomic tests in 5 years – it is around 500,000 tests per year, which is five 
times more than now. The revealed tendency on purchases - annual increase in volume 
more than 100% confirms the given theory about the prospects of this market.  
5.4 General results and suggestion to Case Company 
As a result of the investigation, a possible demand for the equipment was identified - 
sequencers market and the direct quantity of full genome test in conditions of favorable 
influence of the studied factors. The volume of the market and the factors that influence 
the development of this market are predicted. 
According to the opinion of the author, the market for genomic research is very 
promising and the future of disease diagnostics will necessarily include the genome 
test. But at the moment the market is very specific and there are not many players in the 
international market, and even more in the Russian market and as a rule these are large 
concentrators that require large investments in research.  
In author’s opinion, it will be difficult for the Case Company to enter into this market: 
 as a manufacturer - without technology and special ties – the topic is too 
complicated; 
 as a distributor of large companies - main players have already assigned roles.  
But during preparing theoretical background was noticed active work on copying and 
improving technologies by the Beijing Genomics Institute, China. At the same time, in 
the process of communicating with the experts, almost nobody mentioned this Science 
Center and company as known on the Russian market. Case Company has great 
experience with working with Chinese companies and it would be good to study the 
activities of this center in more detail and the opportunities to apply their products on the 
Russian market.  
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The prospect of launching the market of medical research will begin at best in 5 years, 
according to common experts' forecasts and theoretical background. This direction of 
the work from commercial point of view can be evaluated as a distant perspective, 
which must be kept in mind and respond quickly to changes.  
Factors that the company should keep track of if it wants to quickly become involved in 
commercial activities:  
 Improvements of the technology of genome sequencing and reducing the cost of 
the test; 
 When science does not simply decipher the genome, but also makes changes in 
the genome for improve human health; 
 Launch of local Russian projects in this area (production of real products or 
reagents) under conditions of import substitution; 
 Changes in financing conditions (including a genome tests in the insurance or 
budget program); 
 Changes in the legislation on research activity and their connection with medical 
diagnostics; 
 Reduction of registration deadlines; 
 Popularization of genomic tests among commercial services.  
The future is beyond genome research, but when it comes this future is difficult to 
predict, as it will depend on many factors. In order not to miss this opportunity it is 
necessary to keep this subject in view, but at the moment this topic cannot be a "cash 
cow” for the Case Company. 
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6 CONCLUSION 
6.1 Description of the conducted research  
Conducted research under Master’s Thesis achieved the main objective - to understand 
how genome research will develop in Russia on macro level and how it will be 
interesting from the standpoint of commercial activity. Main research question, which 
was established for the research was forecasting of demand of Genome Research on 
Russia market from commercial point of view.  
To fulfill the tasks, the author conducted an analysis of the macro environment and the 
influence factors by PEST analysis, using accessible theoretical materials, modern 
reviews, publications, interviews and articles available on the topic of genomic research 
on the international and Russian markets. Based on the results of this analysis, the 
main influences were determined in the fields of politics, economy, sociality and 
technology. 
In the second step of the study, the author conducted her own research to confirm the 
influence factors, determining their level and the remaining open questions. For the 
study was used a combination of different research methods with the appropriate 
method of analysis. 
The most suitable for the purpose of the study was Qualitative research method with 
division into secondary and primary information.  
Secondary information was collected mainly based on the system of trading of Russian 
state institutions in recent years and related sources, like Registration system. The 
result of the analysis was obtained using the Secondary Information Analysis using the 
‘research question-driven’ approach and the ‘data-driven’ approach.  
The collection of primary information was also divided into three groups, depending on 
the type of respondents. To fully reflect the issue of the genome research from different 
areas, it was decided to receive opinions from three types of respondents: 
- Experts involved in this question through interviews; 
- Sales representatives of Case company through interviews; 
- General public through on-line survey. 
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The analysis of the interviews was conducted using the Content analysis with the use 
of coding text and code matching technology. The analysis of the electronic survey 
was carried out using simple statistical analysis methods, but without the use of 
complex mathematical algorithms. 
6.2 Suggestions for further research 
In the frames of this research it could be advised to the Case Company, as mentioned 
above, to oversee the Asian market - China and possibly Japan and Korea. Their 
technology is developing very quickly and can replace or be much cheaper than the 
existing American huge companies.  
Also, the Case Company mainly focuses on medical activities, in reality the topic of 
genome research is more widely used in the market of research institutes.  
If the company still has the intention to move forward in the field of sequencers and 
reagents, then it is necessary to conduct research on the market of scientific institutes 
and research centers. Since the network of active distributors, based on the results of 
the survey was not suitable for the promotion of a new product, it will be necessary to 
conduct an analysis of the market of commercial organizations involved in the topic of 
sequencing the genome.  
This research was carried out mainly with the forecast of positive changes. Forecast of 
the demand for genomic research made in view of the favorable development of all 
influenced factors. In future research it would be good to determine what will happen if 
these factors have a non-blocking effect. In this case, the basis for researching people's 
readiness for such tests is useful, which in future research could be expanded and also 
the focus could be more on commercial laboratories. 
If go beyond the scope of this narrow topic, in the process of this study, several 
interesting topics were identified that were associated with genomic sequencing, but as 
separate directions:  
 Exom research (selective research of the genome part) 
Interest in this exom research was traced both among experts and ordinary 
people, who did not even know what it is, but were ready to pay and conduct 
some of such tests. Oncology, for example, was the most popular area in 
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answers of people and experts. 
 Biobanks - provision of services for storage of genomic data  
Many experts mentioned the issue of storage, data confidentiality and transfer. 
Now this direction has prospects in Russia - even Google is already engaged in 
something similar. 
If the Case Company is interested in the development and study of other directions, 
these two topics can be interesting and promising for the Russian market, but additional 
information and new research is required.   
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Appendix 1. List of suppliers of sequencers and reagents based on the results of 
state trading in 2012-2017 
Name of company Quantity 
of won 
tenders 
Sum of contracts, 
rubles 
Last date of participation 
in tender 
ООО Компания Хеликон 44 81 039 940,94р, 18.09.2017 4:00 
ООО 'ОРФК' 14 17 692 967,25р, 22.11.2016 9:00 
Общество с ограниченной 
ответственностью «АЛЬБИОГЕН» 25 145 298 007,22р, 10.08.2017 5:00 
Общество с ограниченной 
ответственностью "ГЛ ГЛОБАЛ" 24 22 558 190,00р, 22.12.2016 10:00 
Общество с ограниченной 
ответственностью "Аламед"  21 40 716 319,49р, 25.04.2017 1:00 
Общество с ограниченной 
ответственностью «ИнтерЛабСервис» 22 42 205 372,20р, 08.08.2017 4:00 
Общетво с ограниченной 
ответственностью "Агентство Химэксперт" 
(ООО "Агентство Химэксперт")  22 7 083 035,24р, 29.08.2017 3:00 
Общество с ограниченной 
ответственностью "ДНК-Технология" 19 6 047 347,05р, 26.06.2017 4:00 
Общество с ограниченной 
ответственностью «СкайДжин» 10 3 526 682,27р, 24.07.2017 6:00 
Общество с ограниченной 
ответственностью "ВВВР" 6 8 565 875,76р, 02.11.2015 4:00 
государственное научное учреждение 
Всероссийский научно-исследовательский 
институт ветеринарной вирусологии и 
микробиологии Российской академии 
сельскохозяйственных наук 7 4 962 279,38р, 26.02.2016 3:00 
Закрытое акционерное общество 
"Геноаналитика" 3 2 227 668,20р, 28.08.2017 3:00 
ОБЩЕСТВО С ОГРАНИЧЕННОЙ 
ОТВЕТСТВЕННОСТЬЮ "БИОВИТРУМ" 8 33 440 769,20р, 20.07.2017 3:00 
ЗАО "Акрус" 5 14 104 408,00р, 26.07.2017 5:00 
Общество с ограниченной 
ответственностью "НТЦ Прогресс-
Технология" 7 7 647 900,90р, 04.12.2012 6:00 
Общество с ограниченной 
ответственностью 'РУСХИМБИО' 6 16 998 766,10р, 21.07.2017 3:00 
ООО "Диаэм" 2 2 067 426,00р, 07.11.2016 23:00 
"Литех"  7 19 623 723,09р, 06.06.2017 2:00 
Общество с ограниченной 
ответственностью «Балтмединцентр» 6 9 487 690,35р, 27.05.2016 5:00 
 «Брянскзооветснаб-ЮГ» 5 16 254 142,59р, 21.07.2017 3:00 
ЗАО 'БиоХимМак Диагностика'  5 5 183 430,00р, 04.04.2017 3:00 
Общество с ограниченной 
ответственностью «ГенЭра» 5 4 442 185,65р, 10.12.2015 10:00 
Общество с ограниченной 
ответственностью "ПРОФИЛАБ" 5 4 296 965,24р, 19.08.2016 3:00 
 
 
  
Appendix 2. Protocol of an interview with an expert 
Comment: All interviews were conducted in Russian language; this protocol was 
translated into English specifically for this document and may contain inaccuracies in 
the translation. 
Codes Name of respondents: 
wished not to be published 
Specialization: 
microbiology 
Education: Candidate of 
Biological Sciences 
Region (city):Saint-Petersburg 
Place of work: Private laboratory 
Area: clinical practice 
Date of interview:  
02.08.2017 
Place: office 
Interviewer: Kazimirova 
E. 
 
 
What is your experience in genome research tests? 
I am a Candidate of Biological Sciences; also I passed postgraduate studies in the 
Department of Molecular and Radiation Biophysics of the Petersburg Institute of 
Nuclear Physics, RAS. Area of my scientific and practical interests: cell biology, 
genetics, genome stability, genetic engineering, immunotherapy of oncological 
diseases using dendritic cells, cell cultures, autohemotherapy, genetic diagnostics, 
genotyping of humans, functional genomics.  
Now our laboratory center is widely represented in Saint-Petersburg and in other 
nearby regions. Routine DNA studies are performed using PCR. Recently we have 
established a mass spectrometer for research purposes.  
 
 
RRC 
And do you have any experience of using sequencers in general and new 
generation sequencers in particular? 
I collaborated with the St. Petersburg Research Center on the decoding of the gene for 
research purposes. In principle, there are very few acting sequencers in the city, and 
even in Russia. But, as a rule, the centers for research work co-operate if they set an 
interesting task for them to study.  
America 
 
 
 
 
 
Illumina 
 
Roche 
How do you evaluate developments on the world market?  
This is a very promising direction. Americans are very active in the topic of sequencing 
the genome, their development is quite progressive, a decade ago the task of 
complete decoding of the genome seemed impossible, then the development allowed 
it to be done, but millions of dollars were spent on it and years of working were 
needed. Now any person can do it. In developed countries, such tests are even put on 
stream. Very great success was achieved by the company Illumina - their sequencers 
occupy a large share of the world market. I have experience with this analyzer.  
Recently, Roche has been gaining momentum - they buy up all the exciting start-ups, 
as I think, and quickly realize them in action. They are also a pharmaceutical company 
- and genome research provides a great prospect for this - to monitor how the 
pharmacy will influence the treatment, taking into account all the specifics of the 
genome features. 
China And what about the Asiatic scientists, have the Chinese not yet copied their 
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Illumina 
China 
 
technology? 
I heard about their development and copying, in my Illumina, but at international 
conferences or exhibitions I did not meet their developments.  Of course, the Chinese 
are good fellows and quickly copy everything; I hink they certainly have something in 
their work that can substantially down the market. After all, the main problem why 
sequencing is not done for every patient is it’s a significant cost.  
 
Expensive 
 
Bioinformatics 
 
 
 
 
 
 
 
Expensive 
 
And why are the tests so expensive? 
I think it's expensive, mainly because it's hard to decipher. After all, the result is not a 
ready report with a description of all the features of a person’s genome, but a so-called 
genomic code. Specialists who do this are very rare and highly skilled. Bioinformatics 
is engaged in deciphering, but informatics or biologists are spread in our country (and 
abroad), and bioinformatics is a relatively new specialization. For such specialists the 
future is excellent - so if you do not know where your children are going to study, this is 
an excellent option for the future. 
And equipment and reagents - they are expensive? 
Here the method is even more important. Companies like Illumina and Roche have 
invested a lot of money in their development, so the technique on analyzers is very 
expensive. Of course they will put their costs in equipment and materials. But by the 
way, sequencers are essentially an open system and reagents can be used "not 
original", but simply the market of offers is so small that customers prefer to use what 
is supposed by the method. 
 
Skolkova 
America 
RRC 
Import 
substitution 
What do you think about Russian developments? 
I have met a lot of information about the beginning of development, in Skolkovo they 
are actively working on it. But to be honest now, the main titans are Americans and it 
will be difficult for Russians to catch up with them. But now actively seeking to replace 
all imports – maybe the government can and will stimulate Russian science centers in 
this direction.  
And I read an article about the promising Russian sequencer Nanofor, is not it? 
This is the previous generation, the so-called capillary sequencer. Yes, it can be used, 
but it's already past. In general, in Russia there was a boom about 5 years ago and 
many have installed analyzers of this type. But their technology is old for today. Many 
of them are still used, but it will go to waste because the sequencer of the new 
generation does the same work, but for less money and time 
 
Cost of test 
 
 
 
 
 
 
What do you think is the future of this direction? 
Insanely promising. The world is waiting for when the cost of full genome will cost not 
2-3 thousand dollars as of now, but 100 dollars. Many developments have already 
announced such statements, but in practice have not yet met them. 
And in Russia? 
Now the Russian market has slowed down a bit. As I said, there was a boom when in 
the research institute installed these devices, but in fact they are not used, because 
they do not know how and for what. 
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Private lab 
 
 
Government  
Medical 
program 
Registration 
 
I met information that in 2015 hundred and twenty devices were delivered across 
Russia, but only 20 of them work, it seems like the truth? 
Yes, something like that. True, recent years have increased the genome test service of 
private laboratories, but you know they do not always have their own equipment and 
often turn to the same scientific institutions on a fee basis. 
So there was an interview with the head of the laboratory network popular in Russia, 
where he very accurately reflected the mood in this area - everyone is waiting where 
these technologies and government factors will go in future, especially the acute issue 
of registration.  Now many do not know if they need it. If the sequencing is included in 
the medical program, then this is one thing, if not, then the development will be quite 
different. 
 
 
 
 
 
 
 
 
 
Medicine 
usage 
And in your opinion is it necessary to use the genome research in medicine?  
If the test is conducted as it is now - I'm not sure. For many diagnostics, more routine 
and most importantly cheap PCR tests are suitable. Moreover, such a question arises - 
the person has learned everything about himself by genome test - and what's next. So 
I conduct such a test about myself, well, I know what kind of predisposition - and 
what's the use? I cannot do anything about it - science is just working on it. By the way 
- there is a very ineffective development on the make correction of the genome “Crispr” 
– I can send you information. When science comes to decipher and correct the 
genome, then it will be excellent. 
Although of course in some cases, widespread use in medicine would be useful, in my 
opinion oncology is certainly the main direction. But there is such a thing as research 
of exom - more pre-study of the genome, it's faster and cheaper, this practice is more 
real in my opinion. 
If genomic researches become available on the prescription of a doctor, this could 
simplify many activities, like treatment, in the course of oncology, for example. 
People to pay 
 
Expensive 
And if they are not included in the medical program, are people ready to pay? 
Judging by the fact that the supply in the market is growing – yes. Certainly not in such 
a mass version, because the research is expensive, but there are always well-off 
people who want to know everything about themselves. 
Market  
 
Medical 
market 
 
 
 
Medical 
program 
 
How do you think we can determinate volume of the equipment market and the 
market for research? 
Well here it is necessary to divide into the research market and the medical market.  
In a prospective forecast, each research institute with a corresponding specialization 
should have a equipment. Here we are talking not only about human DNA, but also 
animals, bacteria and other – for example now actively using this theme in population 
research (to know where and where people are moving).  
If the sequencing is included in the medical diagnostics program, then we can say that 
every large laboratory (at least central in the region) will need to have it - that's how to 
calculate. 
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Appendix 3. Report on the study of respondents of the group "Ordinary People" 
Comment: The survey and basic system reports were conducted in Russian language; this report contains is a translation and search of results for 
this survey.  
Date Age Place of 
residence 
(city) 
Position/ 
specialization 
Average 
monthly 
income 
level 
Are you 
familiar with 
the concept of 
sequencing of 
the genome? 
Are you ready to 
pay $ 3,000 to 
fully decrypt your 
genome and know 
about all the 
predispositions? 
How much 
do you 
think 
should 
such a test 
cost in 
USD (not 
more 
than)? 
If there is not a 
possibility of full 
research but to 
study only parts 
of the genome 
associated with a 
certain area (eg 
predisposition to 
breast cancer, or 
mutation gene), it 
would be 
interesting 
Which areas are most 
interesting? 
Would you 
prefer to do 
such a test in 
a private clinic 
or state? 
10.10.2017 35 SPB Office worker Middle Yes No 500 Yes Oncology State 
11.10.2017 30 SPB Scientist Low No No 500 No Oncology, Mutations State 
13.10.2017 25 SPB Employee of 
the budgetary 
sphere 
Middle No No 100 Yes Oncology, Mutations, 
Releted 
State 
10.10.2017 18 Sochi Student Middle No No 500 Yes Mutations State 
16.10.2017 42 Moscow Office worker Middle No No 500 Yes Oncology, Mutations, 
Releted 
State 
17.10.2017 72 SPB Pensioner Middle No Yes 1000 Yes Oncology, Mutations State 
18.10.2017 20 SPB Student Low No No 100 Yes Oncology, Mutations State 
19.10.2017 52 Moscow Office worker Middle Yes Yes 500 Yes Oncology, Mutations State 
20.10.2017 42 SPB Office worker Middle No No 1000 Yes Oncology, Mutations State 
21.10.2017 36 S SPB Business 
owner 
Middle No Yes 500 Yes Oncology State 
22.10.2017 19 SPB Student Middle No Yes 1000 Yes Oncology State 
10.10.2017 42 Novgorod Office worker Middle No No 100 Yes Oncology State 
24.10.2017 47 Novgorod Technical 
worker 
Middle No No 500 Yes Oncology, Mutations State 
17.10.2017 35 Sochi Office worker High No Yes 1000 Yes Oncology State 
1(3) 
 
 
 
 
17.10.2017 36 Sochi Office worker High Yes Yes 500 Yes Oncology State 
17.10.2017 32 Pskov Employee of 
the budgetary 
sphere 
Middle No No 1000 Yes Oncology, Mutations State 
10.10.2017 30 Novgorod Technical 
worker 
Middle No Yes 100 Yes Oncology State 
10.10.2017 28 SPB Office worker High No Yes 500 Yes Oncology State 
24.10.2017 26 SPB Employee of 
the budgetary 
sphere 
Middle No No 1000 Yes Oncology State 
24.10.2017 23 SPB Office worker High No Yes 500 Yes Oncology State 
10.10.2017 49 Pskov Office worker Middle No No 100 Yes Oncology, Mutations State 
10.10.2017 52 SPB Employee of 
the budgetary 
sphere 
Low Yes No 500 No Oncology, Mutations, 
Releted, Other 
State 
10.10.2017 67 SPB Pensioner High No Yes 1000 Yes Oncology State 
10.10.2017 58 SPB Business 
owner 
Middle No Yes 500 Yes Oncology, Mutations, 
Releted 
State 
24.10.2017 23 Krasnoyarsk Office worker Middle No Yes 1000 Yes Oncology, Mutations, 
Releted 
State 
24.10.2017 47 SPB Office worker High No Yes 500 Yes Oncology, Mutations State 
24.10.2017 32 SPB Office worker Middle No No 1000 Yes Oncology, Mutations State 
24.10.2017 35 Moscow Technical 
worker 
Low No No 500 Yes Oncology, Mutations State 
24.10.2017 48 SPB Business 
owner 
High Yes Yes 1000 Yes Oncology, Mutations State 
24.10.2017 67 Pskov Pensioner Middle No No 100 Yes Oncology State 
24.10.2017 45 SPB Office worker High No Yes 500 Yes Oncology, Mutations State 
24.10.2017 31 Pskov Office worker Middle No Yes 500 Yes Oncology, Mutations State 
10.10.2017 58 SPB Business 
owner 
Middle No Yes 500 Yes Oncology, Mutations, 
Releted 
State 
18.10.2017 26 Krasnoyarsk Office worker Low No No 1000 Yes Oncology, Mutations, 
Releted 
State 
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24.10.2017 24 Krasnoyarsk Office worker Middle No Yes 500 Yes Oncology, Mutations State 
24.10.2017 47 SPB Office worker High No Yes 500 Yes Oncology, Mutations State 
18.10.2017 32 SPB Office worker Middle No Yes 500 Yes Oncology, Mutations State 
24.10.2017 35 Pskov Technical 
worker 
Low No No 500 Yes Oncology, Mutations State 
 
Summary conclusions  
Age group Ready to 
pay 
Not ready to 
pay 
TOTAL  City group Ready to 
pay 
Not ready 
to pay 
TOTAL  Income group Ready to 
pay 
Not ready 
to pay 
TOTAL 
18-24 
4 4 8 
 Moscow, 
SPb 16 10 26 
 
Low 0 8 8 
25-34 5 6 11  Big city 4 4 8  Middle 11 12 23 
35-49 7 8 15  Small town 2 6 8  High 11 0 11 
Older then 49 6 2 8           
TOTAL 22 20 42  TOTAL 22 20 42  TOTAL 22 20 42 
  
  
Desired price of the test  Area of interest - quantity of answers   Place of test  
Cost/test 
Quantity of 
answers 
 Area Quantity of 
answers 
 Place Quantity of 
answers 
$100  7  Oncology 40  Private 4 
$500 21  Gene Mutations 27  State 38 
$1000 14  Predisposiotion to chromic diseases 7    
TOTAL 42  Other 1  TOTAL 42 
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